Identifying Barriers to Cervical Cancer Screening in Rural Women

Lacey T. Parkman

Edson College of Nursing and Health Innovation, Arizona State University

Author Note

Lacey T. Parkman is a women's health nurse practitioner student at Edson College of Nursing and Health Innovation, Arizona State University.

She has no known conflict of interest to disclose.

Correspondence should be addressed to Lacey T. Parkman, Edson College of Nursing and Health Innovation, Arizona State University, Downtown Campus, 550 N. 3rd Street, Phoenix,

AZ 85004. Email: ltparkma@asu.edu

Abstract

Problem Statement & Purpose: Cervical cancer screening rates for a Federally Qualified Health Center (FQHC) in rural Northern Arizona is 78%, which is below the Healthy People 2030 goal of 84.3%. Identification of socioeconomic barriers unique to rural women through the use of an intake survey can improve cervical cancer screening rates. This project was guided by the Social Cognitive Theory (SCT). SCT proposes that behavioral change is determined by environmental, social, personal, and behavioral elements.

Methods: At a one-day well-woman event called, "See, Test, and Treat" hosted by the FQHC, an anonymous intake survey was implemented that identified participant demographics, basic cervical cancer knowledge, and perceived socioeconomic barriers to routine cervical cancer screening. Participants were recruited through the FQHC. Participant inclusion criteria: Arizona resident, uninsured, underinsured, 21-65 years old, English or Spanish speaking.

Results: Descriptive statistics were utilized to evaluate the survey responses, reliability, and validity of responses unknown due to self-reported responses. A total of 18 surveys were completed with a final yield of (n = 10). Surveys didn't identify barriers to routine cervical cancer screening; however, an unawareness of cervical cancer risk factors including multiple sexual partners (n = 5, 50.00%), sex at an early age (n = 4, 40.00%), and misperception that cervical cancer is genetic (n = 7, 70.00%) was identified.

Implications for Practice: A need for cervical cancer education exists within the surveyed community. Providing rural women with knowledge regarding cervical cancer can improve screening rates.

Keywords: rural women, cervical cancer screening, socioeconomic barriers

Identifying Barriers to Cervical Cancer Screening in Rural Women

Cervical cancer is a prevalent and devastating cancer that primarily affects women between the ages of 35 to 44 (American Cancer Society [ACS], 2021). Approximately 93% of cervical cancer cases can be prevented with cervical cancer screening (Centers for Disease Control and Prevention [CDC], 2020). Cervical cancer screening detects cellular changes in the cervix and the presence of HPV through Papanicolaou (pap) smear testing (The American College of Obstetricians and Gynecologists [ACOG], 2020). Therefore, the U.S. Preventive Services Task Force (USPSTF) recommends cervical cancer screening for women ages 21 to 65 years old. The type of screening and frequency of screening is recommended based on the patient's age (U.S. Preventive Services Task Force [USPSTF], 2018). Overall, increasing cervical cancer screening rates among women can help prevent cervical cancer by detecting abnormal cytology and the presence of HPV (ACOG, 2016).

Background & Significance

Approximately 99% of cervical cancer is caused by the Human Papilloma Virus (HPV), a sexually transmitted disease (World Health Organization [WHO], 2021). There are 15 high-risk types of HPV, with the most prevalent high-risk strains known as HPV 16 and HPV 18 (Beckmann et al., 2019). Additionally, the U.S. cases of cervical cancer are 14,500 women per year and the mortality rate is 4,290 women per year (ACS, 2021). With these statistics in mind, there are several risk factors for cervical cancer. These risk factors include multiple sexual partners, the first age of intercourse below 18 years old, having a male sexual partner who has had a sexual partner with cervical cancer, smoking, HIV, organ transplant, sexually transmitted infection, diethylstilbestrol (DES) exposure, history of cervical cancer, history of high-grade

squamous intraepithelial lesions (HSIL), and infrequent or absent cervical cytology screening tests (Beckmann et al., 2019).

Purpose and Rationale

A national health initiative developed by the CDC provides free breast and cervical cancer screening, diagnostic testing, and treatment to low-income, underinsured, and uninsured women to help bridge the gap in health care access (CDC, 2021). Another national health initiative created to improve cervical cancer screening is Health People 2030. The Healthy People 2030 objective is to increase the proportion of women who receive cervical cancer screening to a baseline of 80.5% and a target goal of 84.3% (USDHHS & ODPHP, 2020).

Currently, the cervical cancer screening rate for the rural Northern Arizona health care organization is 78%, which is below the target goal of 84.3% set by the Healthy People 2030 national initiative (USDHHS & ODPHP, 2020). Improving cervical cancer screening rates can help diminish the rates of cervical cancer through the detection of high-risk HPV, cervical dysplasia, or cervical intraepithelial neoplasia (ACOG, 2016). Overall, identifying socioeconomic barriers to health care access for rural women can promote evidence-based interventions that positively affect cervical cancer screening outcomes.

Internal Evidence

The rural health care organization in Northern Arizona has identified soft data that impacts their routine cervical cancer screening rates. This soft data includes socioeconomic barriers, population education, and provider education. Furthermore, the socio-economic barriers that are the strongest predictors of deficient cervical cancer screening are rural location and insurance coverage (Harper et al., 2020).

4

Hard data provided by the key stakeholders shows an average cervical cancer screening rate of 78% for the health care organization located in Coconino County, Arizona. Although this rate does not seem significant, the Coconino County health care facility is the only location within the organization that did not see change, positive or negative, in their cervical cancer screening rates within the last year.

PICO

Overall, the soft and hard data identified by the health care organization is clinically significant and identifies potential community barriers to routine cervical cancer screening. Therefore, the data identified by the health care organization has led to the question, "in women dwelling in rural communities (P), how does administering a screening tool that identifies socioeconomic barriers to cervical cancer screening (I), compared to no screening tool (C), affects cervical cancer screening rates (O)?"

Evidence Synthesis

Search Strategy

An exhaustive review of current evidence was utilized to answer the PICOT question. Three databases were used to gather research including PubMed, ProQuest, and Cochrane as well as a review of the grey literature and hand-searching of references. Likewise, the databases were searched using keywords that addressed the components of the PICOT question. Words used to search for the population were combined using the Boolean connectors and included *rural women, United States, cervical cancer, cervical cancer screening, cervical cancer screening rates,* and *United States rural women.* Intervention search words include *screening tools, screening interventions, screening barriers,* and *cervical cancer screening barriers.* Filters utilized included publications between the years 2016-2021, English language, and peerreviewed journals. Inclusion criteria included rural women and cervical cancer screening. Exclusion criteria included studies greater than five years old.

Cochrane

An initial search in Cochrane with the keywords *screening tool* and *cervical cancer* produced 4,022 results. To reduce the number of results, keywords *rural women* were added. The final search with these limitations and keywords produced 56 results. These 56 results were further reduced to a final yield of 10 studies through a rapid critical appraisal.

ProQuest

The initial search in ProQuest utilized the database PsychInfo and the keywords *United States rural women, cervical cancer,* and *screening barriers* with filters placed for results after 2016. This initial search yielded seven results. The final search was done through ProQuest utilizing 58 different databases and the keywords used were the *United States, rural women, cervical cancer screening rates,* and *screening interventions* which produced 3,920 results. These final results were further reduced through rapid critical appraisal and exclusion of predatory journals. Overall, 15 articles were retained for the applicability to the PICOT questions and their high level of evidence.

PubMed

The initial search in PubMed with the keywords *rural women, United States,* and *cervical cancer* yielded 283 results with the limits of 2016 or more recent. To narrow results, additional searches were conducted utilizing the keywords the *United States, rural women, cervical cancer screening barriers,* and *screening tools.* The final search using *cervical cancer rates* and *screening tools* produced 67 results. Additional searches using the keywords *cervical cancer screening* and *rural women* were utilized to find studies outside of the United States that were

6

qualitative, cross-sectional, or quantitative as these types of studies were limited in the US studies. The search yielded 363 results. After further appraisal through the rapid critical analysis, six studies were chosen due to the type of study, level of evidence, and validity.

Critical Appraisal

The rapid critical appraisal checklist developed by Melnyk and Fineout-Overholt (2019) was used to determine the quality of the chosen articles. Overall, the quality of the evidence was moderately high due to most studies being qualitative, a systematic review, or cross-sectional surveys without bias. Although the studies had different sample sizes and were conducted over different periods (see Appendix A, Table A1), the sample characteristics were similar. The majority of participants were women in rural settings between 35-65 years of age. All of the studies focused on different factors affecting cervical cancer screening in rural women. Four studies focused on cervical cancer screening barriers, three studies focused on patient knowledge of cervical cancer risks, and three studies focused on cervical cancer screening interventions. All studies produced similar concepts; geographical location correlates with cervical cancer screening uptake and cervical cancer risk knowledge. Studies focusing on interventions showed a significant increase in cervical cancer screening uptake compared to control groups.

Overall, evidence shows that defining and addressing specific socioeconomic barriers unique to rural women will improve cervical cancer screening rates. Common socioeconomic barriers identified in the literature exist at individual, institutional, community, and public policy levels. These themes include decreased cervical cancer screening follow up, negative family and social influences, decreased cervical cancer screening knowledge, fear or embarrassment of screening, convenience, self-efficacy, time, medical mistrust, and cost (Atere-Roberts et al., 2020; Binka et al., 2019; Hall et al., 2018; Liu et al., 2017; McGinnis et al., 2017; Megersa et al., 2020; Moss et al., 2017; Wang et al., 2019; Weng et al., 2020; Yang et al., 2019). Applying this evidence to rural women in Coconino County by developing a screening tool to identify socioeconomic barriers to cervical cancer screening can pave the way for specific intervention development. Additionally, common interventions identified in the literature utilized to address decreased cervical cancer screening rates include increasing patient education, reducing structural barriers, decreasing costs, and increasing health care provider access (Atere-Roberts et al., 2020; Barrington et al., 2019; Falk et al., 2018; Smith-Gagen et al., 2019).

Theory Application

The outcomes suggested by the evidence apply to the Social Cognitive Theory (SCT) (see Appendix B, Figure 1). SCT proposes that behavioral change is determined by environmental, social, personal, and behavioral elements, and all of the elements influence one another (Bandura, 2004). The main concepts of SCT include self-efficacy and the ability to control health outcomes, outcome expectations such as benefits versus risks of health habits, an individual's health goals, and hindrances to overall health changes (Bandura, 2004). The four studies that identified barriers to cervical cancer screening in rural women had a common theme of self-efficacy, the ability of an individual to believe in themselves and obtain a certain outcome (Bandura, 2004). Likewise, the three studies focused on rural women's concept of cervical cancer risks help promote increased self-efficacy and cervical cancer screening uptake through patient education. Additionally, this self-efficacy can lead to improved cervical cancer screening, which further leads to goals of increased screening compliance. The four studies that reviewed barriers to cervical cancer screening correlate with the impediments portion of SCT (Bandura, 2004). Led to the three studies focused on cervical cancer screening interventions to overcome identified barriers. Overall, all of these studies reinforce the impact of environmental, social,

personal, and behavioral elements on behavioral change, specifically in rural women, and cervical cancer screening rates (Bandura, 2004). Change can be promoted through knowledge of health risks and the implementation of interventions to overcome socioeconomic barriers in rural women.

Only two of the studies explicitly stated the use of SCT. However, the remaining studies infer a health promotion model to better understand the influences of different factors and their impact on cervical cancer screening. Lastly, these factors are considered when developing interventions. For example, geographical location is a negative indicator of cervical cancer screening rates; therefore, interventions developed helped overcome geographical locations by use of patient navigators or telehealth services (Atere-Roberts et al., 2020; Barrington et al., 2019; Falk et al., 2018).

Overall, SCT is an appropriate guiding framework for the proposed evidence-based practice project, developing a screening tool that identifies socioeconomic barriers in rural women. This framework is appropriate because behavioral change is influenced by environmental, social, personal, and behavioral elements (Bandura, 2004). Therefore, evaluating socioeconomic barriers can identify specific barriers that can be addressed and overcome to improve cervical cancer screening rates in rural women as well as other preventive health services.

Implementation Framework

The implementation of this project is guided by the Lean Sigma Six framework (see Appendix B, Figure 2). This framework promotes work standardization and is fact-based and data-driven. The five components of Lean Sigma Six include *defining, measuring, analyzing, improving,* and *controlling* (American Society for Quality [ASQ], 2021). This framework is an

appropriate fit for the evidence-based practice project due to its ability to define socioeconomic barriers to cervical cancer screening in rural women, as well as its ability to define the selected intervention. Next, the framework can measure intervention outcomes, analyze areas of strengths and weaknesses, and provide opportunities for improvement. Finally, once the intervention has been evaluated through the Lean Sigma Six components, it can be fine-tuned until it is efficient and controlled (ASQ, 2021).

The Lean Sigma Six framework components build upon one another and are a processoriented approach that helps lead providers to develop focused interventions (ASQ, 2021). The first step in this approach defines the socioeconomic barriers faced by rural women in Coconino County, Arizona. Next, these specific socioeconomic barriers can be measured and analyzed to develop an intervention to improve cervical cancer screening. Subsequently, this intervention is also subjected to the SCT and Lean Sigma Six framework to measure and analyze strengths and weaknesses to further refine and adapt the intervention to best address the socioeconomic barriers of rural women in Coconino County and improve cervical cancer screening outcomes (ASQ, 2021).

Methods

Ethical Considerations

Ethical principles should be evaluated when implementing a project to ensure participant and organization rights are protected. The development and utilization of a screening tool to evaluate socioeconomic barriers in rural women require the evaluation of several ethical factors, including intrapersonal, interpersonal, and organizational factors (Boutin-Foster et al., 2013; Stanford University, n.d.). Intrapersonal factors include the participant's knowledge, attitude, and individual behaviors towards cervical cancer screening. Next, interpersonal factors include potential ethical considerations such as the provider-patient interaction. Developing a screening tool evaluating socioeconomic barriers to cervical cancer screening can promote the ethical principle of beneficence and justice by allowing equal preventive screening to participants despite barriers to health care access. Lastly, organizational factors such as rules and policies will promote non-maleficence by ensuring optimal evidence-based practice is utilized in participant screening and that participant information will be de-identified and stored appropriately according to the facility's requirements (Boutin-Foster et al., 2013; Stanford University, n.d.).

Human Subject Protection

Human subject protection will be ensured through the use of written informed consent (see Appendix C). Written informed consent will be provided before the initiation of the written project survey. This informed consent will outline the purpose of the survey and will ensure the participant that no identifying personal information will be obtained. Likewise, the participant will be assured that they may skip questions or stop the survey at any point. Overall, written informed consent will be provided to participants to provide participants with autonomy in decision-making processes.

Project Setting

The setting for the EBP project is an FQHC in rural Northern Arizona. The health care facility provides several services including behavioral health, care management, dental, diabetes support, lactation & breastfeeding support, OB/GYN, pediatrics, pharmacy, physical therapy, primary care, and virtual visits. A service developed and executed at this facility to address the health needs of the rural and underserved female population is the Well Woman HealthCheck Program (Arizona Department of Health Services [ADHS], 2021). The Well Woman HealthCheck program implements a one-day event called "See, Test, and Treat" that provides

comprehensive services such as clinical breast exams, mammograms, pelvic exams, and cervical cancer screening (ADHS, 2021).

Stakeholders

Key stakeholders for this event include personnel who work for or with the FQHC in Coconino County. This personnel includes program coordinators, program managers, education directors, women's health providers, event participants, and their families, as well as ancillary personnel vital to coordinating and implementing the one-day event.

Participants who are recruited for the one-day event through the health care organization's Well Woman HealthCheck Program must meet certain criteria. Inclusion criteria are women who are Arizona residents, uninsured or underinsured, between the ages of 21 to 65, below the poverty level or economically disadvantaged, and English or Spanish speaking. Exclusion criteria are women who are non-Arizona residents, below 21 years old, are not a participant of the "See, Test, and Treat" event, has Medicare Part B, have Arizona Health Care Cost Containment System (AHCCCS), or is currently diagnosed with cervical cancer.

Project Description

Project Instrument

The survey utilized at the one-day event was developed by Akinlotan et al. (2017). This survey was chosen due to its population and setting similarity to Coconino County. The survey identifies participant demographics, perceived physical and mental health, basic cervical cancer knowledge, perceived socioeconomic barriers to health care, family cancer history, and HPV vaccination knowledge and status (see Appendix D). This survey will be vital to the health care organization to address and overcome barriers to routine cervical cancer screening within their

community, which will ultimately promote practice change and the development of an intervention to overcome identified socioeconomic barriers to routine cervical cancer screening.

Project Timeline

The timeline of project implementation includes the use of the survey developed by Akinlotan et al. (2017) at the "See, Test, and Treat" event on September 18, 2021. This survey will be provided to both English and Spanish-speaking participants through the utilization of Citi-trained interpreters. After the event, the surveys will be analyzed and evaluated to determine statistically significant information that will be provided to the health care organization to determine socioeconomic barriers to routine cervical cancer screening as well as populationspecific cervical cancer risk knowledge and the potential need for participant's education.

Data Analysis

A total of 50 participants received cervical cancer screening at the "See, Test, and Treat" event on September 18, 2021. Additionally, 17 project surveys were collected from women who met the inclusion and exclusion criteria. The collected surveys will be analyzed and evaluated through Intellectus to identify statistically significant data that can be utilized by the health care organization to address and improve participant and population outcomes.

"See, Test, and Treat" Event Budget

Cost Reimbursement

Cost Reimbursement (Actual Expenditures)	Approved Budget
Federal Personnel	\$94,000.00
State Personnel	\$30,000.00
Federal Screening	\$60,000.00
Navigation Only	\$6,600.00
State Screening	\$6,000.00
State Other Operating Expenses	\$3,000.00
State Indirect Expenses	\$3,500.00
ADOT Screening	\$12,000.00
Total	\$215,100.00

Category	Requested Grant Amount
Medical Equipment	\$0
Exam, Laboratory, and Testing Supplies	\$0
Temporary Program Coordinator	\$4,000.00
Support Personnel	\$4,000.00
Marketing/Promotion	\$2,500.00
Translation Services (print materials and	\$0
on-site)	
Transportation	\$0
Children's Activities	\$272.00
Meals	\$2,500.00
Total Requested Amount	\$13,272.00

Approved Grant Supplied by College of American Pathologists

Funding Sources

Approved Grants	Contribution
National Breast and Cervical Cancer Early	NBCCEDP will cover allowable procedures
Detection Program (NBCCEDP)	and relevant CPT codes (see Appendix E)
Arizona Department of Health Services	\$215,100.00 (Indirect rate 22.71%)
College of American Pathologists	\$13,272.00
Arizona Complete/Health Care First	Approved – unknown amount

Budget Justification

After the event, the Well Woman Health Check Program provides all the follow-up services for the participants. Likewise, they cover the costs of the screening services provided to the participants as long as the CPT codes fall within the NBCCEDP Allowable Procedures and Relevant CPT Codes (see Appendix E). Lastly, if more services are provided than anticipated, the Arizona Department of Health Services will provide additional funding to cover the negative costs.

Results

Participant Demographics

The sample consisted of rural women (n = 10) receiving free breast and cervical cancer screening at a Federally Qualified Health Center in Northern Arizona. The sample consists of adults with the average age of the subjects being 47.50 (SD = 12.76) and the ages ranging from 24.00 to 63.00 years. The average Annual Income was 12,514.20 (SD = 14,442.18) which ranged from \$0.00 to \$50,000). Most of the sample lived in Coconino County (n = 9, 90.00%). Half of them attended College (n = 5, 50.00%). Also, over half of them were Uninsured (n = 7, 70.00%) or utilized Private Insurance (n = 3, 30.00%) indicating that over 70.00% were low-income. The majority of the sample was White or Caucasian (n = 5, 50.00%), English speaking (n = 6, 60.00%), and Single (n = 5, 50.00%). Frequencies and percentages are presented in Tables 1 & 2 (see Appendix F).

General Health Demographics

The majority of participants answered Yes (n = 7, 70.00%) to "Do you have a health care provider?" Also, the majority of the sample answered <6 months (n = 7, 70.00%) when asked, "When was the last time you visited your provider?" The majority of the sample described their health as Good (n = 4, 40.00%). Frequencies and percentages are presented in Table 3 (see Appendix G).

The participants were provided a Likert scale ranging from 1 to 5, with 1 being "never" and 5 being "always." The most frequently observed category of "How often do you prepare a list of questions for your doctor?" was Always (n = 4, 40.00%). The most frequently observed category of "How often do you ask questions about the things you want to know and the things you don't understand?" was Always (n = 5, 50.00%). The most frequently observed category of "How often do you discuss any personal problems that may be related to your illness?" was Always (n = 4, 40.00%). The most frequently observed category of "How confident are you in

filling out medical forms by yourself?" was Always (n = 6, 60.00%). Frequencies and percentages are presented in Table 4 (see Appendix G).

All of the participants (n = 10) answered "How many days in the past month was your physical health not good?" with 0.00. The participants' responses to "How many days in the past month has your mental health not been good?" had a mean response of 1.70, with an SD of 3.13. The range was from 0.00 to 10.00. The summary statistics can be found in Table 5 (see Appendix G).

Pap Smear History

In addition to demographics, the survey asked participants about their pap smear history. When asked "Have you had a hysterectomy?" the majority of participants answered No (n = 9, 90.00%). The majority of participants identified their "Last pap smear" as Within the past 1 year (n = 6, 60%). Additionally, the majority of participants answered No (n = 5, 50.00%) to a history of "Abnormal pap smear." They also answered False to "Have you or a member of your family had cervical cancer?" (n = 9, 90.00%). Most of the participants answered No to "Are you aware of the 3-part HPV vaccine series?" (n = 6, 60.00%). Similarly, the majority of participants answered No to "Have you completed the HPV vaccine series?" (n = 9, 90.00%). Frequencies and percentages are presented in Table 6 (see Appendix H).

Cervical Cancer Risk Factors

The participants were provided a 10-item True/False questionnaire to determine cervical cancer risk factor knowledge. Half of the participants responded TRUE (n = 5, 50.00%) to the question "...She has many sexual partners" as a risk factor for cervical cancer. The participant responses were divided, both TRUE and FALSE for the cervical cancer risk factor of "...She

smokes cigarettes" with an observed frequency of (n = 4, 40.00%). Likewise, the risk factor of "...She started having sex at a young age" was also divided between TRUE and FALSE, each with an observed frequency of (n = 4, 40.00%). Nearly half of the participants responded FALSE to the question "...She has unprotected sex" (n = 4, 40.00%). Conversely, the majority of participants responded TRUE to the question "...She does not go for regular pap smear tests" (n = 8, 80.00%), and the majority of responses to "...She has a sexually transmitted disease or virus" was TRUE (n = 7, 70.00%). Nearly half of the participants responded FALSE (n = 4, 40.00%) to the question "...She used birth control pills for a long time." The responses were majority FALSE (n = 5, 50.00%) for the question of "...She has many children." Less than half of the participants perceived "...She has a weakened immune system" as a cervical cancer risk factor with a response of FALSE (n = 4, 40.00%). Lastly, the majority of participants considered cervical cancer to have a genetic risk factor with an (n = 7, 70.00%) TRUE response rate to the question "...It runs in her family." Frequencies and percentages are presented in Table 7 (see Appendix I).

Socioeconomic Barriers to Routine Cervical Cancer Screening

The participants were provided a Likert Scale survey that identified perceived socioeconomic barriers to routine cervical cancer screening. The responses ranged from 1 to 5, with 1 being "Strongly Disagree" and 5 beings "Strongly Agree". The majority of participants Strongly Disagreed that "Feelings of embarrassment" (n = 8, 80.00%), "Fear of finding cancer" (n = 7, 70.00%), "Transportation" (n = 9, 90.00%), "Cost" (n = 5, 50.00%), "Anxiety about procedure" (n = 8, 80.00%), "Lack of knowledge" (n = 9, 90.00%), "Lack of time" (n = 9, 90.00%), "Anticipation of pain" (n = 7, 70.00%), "Forgetting to schedule an appointment" (n = 6, 60.00%), "Other health problems" (n = 8, 80.00%), Language barriers" (n = 7, 70.00%),

and "Male physician" (n = 6, 60.00%) were barriers to routine cervical cancer screening. Frequencies and percentages are presented in Table 8 (see Appendix J).

Impact of Project & Sustainability

Identifying barriers to cervical cancer screening through an intake survey can have a positive impact on patients, providers, the FQHC, and policy development. The intake surveys identified a need for cervical cancer risk factor education within the surveyed community. Providing education can improve patient cervical cancer risk factor awareness, which can promote healthy lifestyle changes such as smoking cessation and increased routine cervical cancer screening. Additionally, healthcare professionals can promote improved cervical cancer education at well-woman exams and following up screening results from the "See, Test, and Treat" event. Lastly, the FQHC can promote the sustainability of the DNP project through a continuation of the intake survey. The survey can be revised and adapted to continue to meet the educational needs of the community identified by the participant responses. Additionally, health policy changes can be developed by the FQHC to develop educational resources and services to promote further learning for the community.

Discussion

Project Strengths & Facilitators

The intake survey has several strengths and facilitators for continuation. First, the survey applies to all rural settings because the survey questions are general and not specific to the FQHC community. Next, the surveys were implemented at a one-day event, allowing participants to have ease of accessibility and promote response uptake. Additionally, the survey was translated into Spanish, so more participants were able to respond to the intake survey. Lastly, the survey identified an unawareness of cervical cancer risk factor knowledge, which will

18

allow the FQHC to develop population-specific interventions to overcome this lack of cervical cancer risk factor knowledge.

Project Limitations & Barriers

The intake survey had a few limitations and barriers. First, the inclusion and exclusion criteria for the participants were too narrow. Eight survey responses had to be omitted because participants did not fall in the correct age range or had Medicaid. Additionally, the event was open to the public, but attendees who were not enrolled in the Well Woman HealthCheck Program were not able to participate in the intake survey. Having more broad criteria would allow for a greater range of responses that would better reflect the community. Next, the survey respondents were self-reported, which may influence the accuracy of responses. Similarly, participants were recruited by the FQHC, so the participants were intentional about receiving cervical cancer screening, therefore their knowledge of risk factors may not be an accurate depiction of cervical cancer knowledge for the community. Lastly, the survey was not able to be revised by the FQHC before the event, so the language was not evaluated for its inclusivity. For example, one of the questions used the language "male physician" rather than the more appropriate term "male provider."

Survey Results & Current Literature

The intake survey results correlate with current literature regarding barriers to cervical cancer screening. Although the survey did not identify any socioeconomic barriers to cervical cancer screening, the survey did identify an unawareness of cervical cancer risk factors knowledge. Likewise, the literature identifies education as an influence on cervical cancer screening. The more aware women are of cervical cancer and risk factors, the more likely they

are to receive routine cervical cancer screening (Binka et al., 2019; Liu et al., 2017; Megersa et al., 2020; Weng et al., 2020; Yang et al., 2019).

Future Recommendations

Future recommendations based on the intake survey results include the development of evidence-based interventions to evaluate the impact of education on routine cervical cancer screening. Development of educational interventions can be achieved through the participant, provider, healthcare system, and policy involvement. The healthcare system can develop policy changes to promote educational services and the healthcare providers can facilitate the implementation of the educational services to patients in the community. Evaluation of the educational interventions through a pre and post-test of cervical cancer risk factor knowledge can further evaluate the efficacy of the education and promote further adaptations of education, with the ultimate goal of improving community cervical cancer screening rates.

Conclusion

Designing and implementing a screening tool that identifies socioeconomic barriers to cervical cancer screening in rural women will provide the foundation for future interventions to address the identified barriers to preventive health screenings. Ultimately, if this evidence is utilized to change health practices, it is the goal that cervical cancer screening rates will increase and meet the Healthy People 2030 objective, ultimately improving community health outcomes (USDHHS & ODPHP, 2020). Lastly, it is the future aspiration that the screening tool can be utilized in different populations and adapted to meet different medical conditions to identify and overcome barriers to other health outcomes. Overall, this provides the opportunity to identify and improve multiple barriers to health care services across the healthcare organization, leading to improved patient and community quality of life.

References

- Akinlotan, M., Bolin, J. N., Helduser, J., Ojinnaka, C., Lichorad, A., & McClellan, D. (2017).
 Cervical cancer screening barriers and risk factor knowledge among uninsured women.
 Journal of Community Health, 42(4), 770–778. <u>https://doi.org/10.1007/s10900-017-0316-9</u>
- American Cancer Society. (2021). Key statistics for cervical cancer.

https://www.cancer.org/cancer/cervical-cancer/about/key-statistics.html

- American Society for Quality. (2021). What is six sigma? <u>https://asq.org/quality-resources/six-sigma</u>
- Arizona Department of Health Services. (2021). *Well Woman HealthCheck Program eligibility*. <u>https://azdhs.gov/prevention/tobacco-chronic-disease/cancer-prevention-</u> control/index.php#healthcheck-eligibility
- Atere-Roberts, J., Smith, J. L., & Hall, I. J. (2020). Interventions to increase breast and cervical cancer screening uptake among rural women: A scoping review. *Cancer Causes and Control*, 31, 965–977. <u>https://doi.org/10.1007/s10552-020-01340-x</u>
- Bandura, A. (2004). Health promotion by social cognitive means. *Health Education & Behavior*, *31*(2), 143–164. <u>https://doi.org/10.1177/1090198104263660</u>
- Barrington, W. E., DeGroff, A., Melillo, S., Vu, T., Cole, A., Escoffery, C., Askelson, N.,
 Seegmiller, L., Gonzalez, S. K., & Hannon, P. (2019). Patient navigator reported patient
 barriers and delivered activities in two large federally-funded cancer screening programs. *Preventive Medicine*, 129, 105858. <u>https://doi.org/10.1016/j.ypmed.2019.105858</u>
- Beckmann, C. R. B., Ling, F. W., Herbert, W. N. P., Laube, D. W., & Smith, R. P. (2019).Cervical neoplasia and carcinoma. In *Obstetrics and Gynecology* (8th ed., pp. 389–398).Wolters Kluwer.

- Binka, C., Nyarko, S. H., Awusabo-Asare, K., & Doku, D. T. (2019). Barriers to the uptake of cervical cancer screening and treatment among rural women in Ghana. *BioMed Research International*, 2019. https://doi.org/10.1155/2019/6320938
- Boutin-Foster, C., Scott, E., Melendez, J., Rodriguez, A., Ramos, R., Kanna, B., & Michelen, W. (2013). Ethical considerations for conducting health disparities research in community health centers: A social-ecological perspective. In *American Journal of Public Health* (Vol. 103, Issue 12, pp. 2179–2184). American Public Health Association. https://doi.org/10.2105/AJPH.2013.301599
- Centers for Disease Control and Prevention. (2021). *National Breast and Cervical Cancer Early* Detection Program. https://www.cdc.gov/cancer/nbccedp/about.htm
- Falk, D., Cubbin, C., Jones, B., Carillo-Kappus, K., Crocker, A., & Rice, C. (2018). Increasing breast and cervical cancer screening in rural and border Texas with Friend to Friend plus patient nagivation. *Journal of Cancer Education*, 33, 798–805. https://doi.org/10.1007/s13187-016-1147-6
- Hall, M. B., Vos, P., Bess, J. J., Reburn, K. L., Locklear, G. D., Mcalister, J., & Bell, R. A.
 (2018). Cervical cancer screening behaviors and perceptions of medical mistrust among rural black and white women. *Journal of Health Care for the Poor and Underserved*, 29(4), 1368–1385. <u>https://doi.org/10.1353/hpu.2018.0101</u>

Harper, D. M., Plegue, M., Harmes, K. M., Jimbo, M., & SheinfeldGorin, S. (2020). Three large scale surveys highlight the complexity of cervical cancer underscreening among women 45-65 years of age in the United States. *Preventive Medicine*, *130*, 105880–105880.
 <u>https://pdf.sciencedirectassets.com/272375/1-s2.0-S0091743519X00109/1-s2.0-S0091743519303561/main.pdf?X-Amz-Security-</u>

- Liu, T., Li, S., Ratcliffe, J., & Chen, G. (2017). Assessing knowledge and attitudes towards cervical cancer screening among rural women in eastern China. *International Journal of Environmental Research and Public Health*, 14(9). https://doi.org/10.3390/ijerph14090967
- McGinnis, E., Meyerson, B. E., Meites, E., Saraiya, M., Griesse, R., Snoek, E., Haderxhanaj, L., Markowitz, L. E., & Smith, W. (2017). Cervical cancer screening and prevention in 78 sexually transmitted disease clinics - United States 2014-2015. *Sexually Transmitted Disease*, 44(10), 637–641. https://doi.org/10.1097/OLQ.0000000000000659
- Megersa, B. S., Bussmann, H., Bärnighausen, T., Muche, A. A., Alemu, K., & Deckert, A. (2020). Community cervical cancer screening: Barriers to successful home-based HPV selfsampling in Dabat district, North Gondar, Ethiopia. A qualitative study. *PLoS ONE*, *15*(12). <u>https://doi.org/10.1371/journal.pone.0243036</u>
- Moss, J. L., Liu, B., & Feuer, E. J. (2017). Urban/rural differences in breast and cervical cancer incidence: The mediating roles of socioeconomic status and provider density. *Women's Health Issues*, 27(6), 683–691. https://doi.org/10.1016/j.whi.2017.09.008
- Musa, J., Achenbach, C. J., O'dwyer, L. C., Evans, C. T., Mchugh, M., Hou, L., Simon, M. A., Murphy, R. L., & Jordan, N. (2017). *Effect of cervical cancer education and provider recommendation for screening on screening rates: A systematic review and meta-analysis*. <u>https://doi.org/10.1371/journal.pone.0183924</u>
- Rastogi, A. (2021). *A brief introduction to lean, six sigma, and lean six sigma*. https://www.greycampus.com/blog/quality-management/a-brief-introduction-to-lean-and-

six-sigma-and-lean-six-sigma

Smith-Gagen, J., White, L. L., Santos, A., Hasty, S. M., Tung, W.-C., & Lu, M. (2019). Scopeof-practice laws and expanded health services: The case of underserved women and advanced cervical cancer diagnoses. *J Epidemiol Community Health*, 73, 278–284. https://doi.org/10.1136/jech-2018-210709

Stanford University. (n.d.). What are the basic principles of medical ethics? <u>https://web.stanford.edu/class/siw198q/websites/reprotech/New Ways of Making</u> <u>Babies/EthicVoc.htm</u>

- The American College of Obstetricians and Gynecologists. (2016). *Cervical cancer screening and prevention*. <u>https://www.acog.org/clinical/clinical-guidance/practice-</u> <u>bulletin/articles/2016/10/cervical-cancer-screening-and-prevention</u>
- The American College of Obstetricians and Gynecologists. (2020). *Cervical cancer screening* (update). <u>https://www.acog.org/clinical/clinical-guidance/practice-</u> advisory/articles/2018/08/cervical-cancer-screening-update
- U.S. Department of Health and Human Services, & Office of Disease Prevention and Health Promotion. (2020). *Increase the proportion of females who get screened for cervical cancer* — *C-09 - Healthy People 2030*. <u>https://health.gov/healthypeople/objectives-and-</u> <u>data/browse-objectives/cancer/increase-proportion-females-who-get-screened-cervical-</u> <u>cancer-c-09</u>
- U.S. Preventive Services Task Force. (2018). *Cervical cancer: Screening*. <u>https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancer-screening#fullrecommendationstart</u>

Vancouver, J. B., Thompson, C. M., Tischner, E. C., & Putka, D. J. (2002). Two studies

examining the negative effect of self-efficacy on performance. *Journal of Applied Psychology*, 87(3), 506–516. <u>https://doi.org/10.1037/0021-9010.87.3.506</u>

- Wang, S.-X., Wu, J.-L., Zheng, R.-M., Xiong, W.-Y., Chen, J.-Y., Ma, L., & Luo, X.-M. (2019).
 A preliminary cervical cancer screening cascade for eight provinces rural Chinese women:
 A descriptive analysis of cervical cancer screening cases in a 3-stage framework. *Chinese Medical Journal*, *132*(15), 1773–1780. <u>https://doi.org/10.1097/CM9.00000000000000353</u>
- Weng, Q., Jiang, J., Haji, F. M., Nondo, L. H., & Zhou, H. (2020). Women's knowledge of and attitudes toward cervical cancer and cervical cancer screening in Zanzibar, Tanzania: A cross-sectional study. *BMC Cancer*, 20(1). <u>https://doi.org/10.1186/s12885-020-6528-x</u>
- World Health Organization. (2021). *Cervical cancer*. <u>https://www.who.int/health-topics/cervical-</u> <u>cancer#tab=tab_1</u>
- Yang, H., Li, S. P., Chen, Q., & Morgan, C. (2019). Barriers to cervical cancer screening among rural women in eastern China: A qualitative study. *BMJ Open*, 9(3).

https://doi.org/10.1136/bmjopen-2018-026413

Appendix A

Evaluation and Synthesis Tables

Table A1

Evaluation Table

Citation	Theory/ Conceptual Framework	Design/Method/ Sampling	Sample/Setting (Describe)	Major Themes Studied/Defini tions	Measurement/I nstrumentation	Analysis	Findings	Decision for Use
(Yang et al.,	Inferred	Design: QS	N: 39	IV1:	Semi-structured	Transcribed IDI	Five major	LOE: VI
2019).	HPDPT		n: 21 women	Knowledge of	IDI	& FGD -	themes:	
Barriers to		Purpose: To	n: 14 providers	CC		subjected to		Strengths:
cervical		explore barriers	n: 4 husbands		17-item	thematic	(1) gaps in	Detailed/in-depth
cancer		to free CCS		IV2: Barriers	questionnaire	analysis	knowledge	responses
screening		among RW in	Setting: 2	to CC	(pretest before		of CC and	Relevant information to
among rural		China from the	counties in Jining		interview)	All IDI & FGD	health	policy makers to create
women in		perspective of	Prefecture of	DV: CCS rates		- digitally	awareness	interventions for CCS
eastern		women, HC	eastern China		FGD	recorded		
China: A		providers and					(2) fear of	Weaknesses:
qualitative		husbands	Sample				cancer and	Purposive sampling: May
study			Demographics:				screening	bias findings
			Women:				outcomes	
Funding:			MA: 48					Possible social
China			Ages: 37 to 60				(3) cultural	acceptability bias w/FGD
Medical			years				barriers	
Board Open			Married: 95.2%					QS may limit
Competition			EL: primary or				(4) influence	generalizability for
Grant [Grant			below				of close	different settings
#CMB14-			Previous CCS:				contacts	
195]			52.4%					

Bias: None recognized Country: China			HC Providers: MA 42.6 EL junior college or greater Medical Practitioners: 50% Husbands: MA: 50.7 All: small-hold farmers Inclusion Criteria: Women, Ages 35-64 Resides in study township UE No CCS or failure to attend FU Attrition: None				(5) inconvenien ce	Conclusions: This QS identified common themes among RW in China and their perception of CCS F&A pt. population: The themes identified are F&A to RW and may help HC organizations overcome barriers to CCS.
Citation	Conceptual	Design/Method	Sample/Setting	Major	Measurement	Analysis	Findings	Decision for Use
	Framework			Variables & Definitions				
(Binka et al.,	Socioecological	Design: QS	Group 1:	IV: Barriers to	Group 1: IDIs	3 RA:	Barriers:	LOE: VI
(Dinita et al., 2019).	Model of		N: 15	CCS	5.0up 11.1510	Transcribed	Individual,	
Barriers to	McLeroy et al.	Purpose:	CC patients who		Group 2: IDIs	TRI to English	institutional,	Strengths:
the uptake		To explore the	attended the	DV: CCS rates			community,	Not explicitly stated.
of cervical		barriers to the	gynecology unit	& treatment	FGD	TRI – sent to	& policy-	Potential strengths include
cancer		uptake of CCS	of the Battor			experts for	level	implementing intervention
screening		and treatment in	Catholic Hospital			validity		

andthe North Tonguin the NorthRQD.treatmentdistrict of GhanaTongu District,RQD.among ruralVolta Region,Volta Region,RQD.	A that address the identified barriers
	A barriers
women in Ghana	Weaknesses:
Ghana	Limited sample sizes and
Group 2:	the limited feasibility to
Funding: N: 10	apply this study to other
None stated Women MA 30-	HC settings
	ne settings
65 registered at	Caralatan
Bias: None the Battor	Conclusions:
recognized Catholic Hospital	Several barriers were
who have no CCS	identified that may impact
Country:	CCS. This includes
Ghana FGD:	individual knowledge, and
N: 30	funding for
3 groups	screening/treatment
Ages 35-65	
	F&A
Setting:	pt. population: Although
Battor Catholic	these specific barriers may
Hospital in the	apply to other rural HC
North Tongu	facilities and women, there
District of the	may be different personal
Volta Region,	barriers and specific
Ghana	organizational barriers that
Giialia	may make this study
Sample	difficult to apply to other
	HC facilities.
Demographics:	HC facilities.
Group 1:	
Age 30-50	
EL: Secondary \leq	
Inclusion	
Criteria:	

Citation	Conceptual	Design/Method	Selection based on thematic saturation from the hospital setting Attrition: Group 1: 45, due to death or unable to contact Sample/Setting	Major	Measurement	Analysis	Findings	Decision for Use
	Framework		I man 9	Variables & Definitions				
(Weng et al., 2020). Women's knowledge of and attitudes toward cervical cancer and cervical cancer screening in Zanzibar, Tanzania: A cross- sectional study	Inferred HPDPT	Design: XSS Purpose: To describe RW's awareness of CC and to explore the attitudes toward, acceptability of and barriers to CCS (CCS) in Zanzibar	N: 1483 Setting: 5 wards from 10 administrative districts Sample Demographics: Women MA: 32.86, Majority: Muslim & married MP: 2.96 EL: Secondary Previous CCS: 4.83%	IV: Factors associated w/screening DV: CCS	 33 item questionnaire: general demographics 3 close-ended questions: attitude towards screening 14 close-ended questions: determine awareness of CC 	STATA Pearson Chi- square Fisher's exact tests ANOVA Meta Analyses: Multiple logistic & linear regression model	Women had inadequate knowledge on CCS Screening decision associated with education, family income, and family history of cancer	LOE: V Strengths: Situation-based use of a mixed refinement of previous questionnaires Face-to-face interviews that were double checked The study was conducted in all districts of Zanzibar, including remote rural areas, which could to some extent represent the cognitions of and attitudes toward CC and screening in the general population in
Funding: National Natural			Inclusion Criteria: Women ages 14-65					Zanzibar

Science Foundation of China (81701475)	Attrition: 17	The first to indicate that schistosomiasis infection was a significant positive predictor of CCS uptake
Bias: None recognized		Weaknesses: The district effect on women's willingness to
Country: China		participate in free or non- free screening was not checked
		Cross-sectional studies only show implied correlation
		Conclusions: This study showed the need for education to promote CCS and diminish misperceptions of CC causes
		F&A pt. population: This cross- sectional study specifically applies to the 5 wards chosen within the 10 districts, although several of the correlations may pertain to different RW, the outcomes may not be the same.

Effect of cervical cancerPurpose: To evaluate the effect of CC education and PE on CCS rateswere chosen from several countries: interventionsCC education on interventionsReview Manager smitherintervention significantly increasedsearch, study guided by published SR protocol upublished SR protocoland provider recommenda tion for screening on screening rates: A SR analysisOCS ratesForwider recommendatio na2. Provider recommendatio nHeterogeneity: statistic.COS ratesConclusions: SR suppon to us first conclusions: SR suppon to us (HPV)Funding: Grant #D43TW00Sample Demographics: URATIONDV: participation criteria: RCT, clusier RCT, clusier RCT, clusier RCT, clusier RCT, duasi- clusier RCT,	Citation	Conceptual Framework	Design/Method	Sample/Setting	Major Variables & Definitions	Measurement	Analysis	Findings	Decision for Use
2017).Setting: Studies were chosen from cervical cancer education and PE on CCS ratesSetting: Studies were chosen from address cervical education and PE 	Citation	SCF & SEM	Design: SR &	N: 28 studies	IV1: CC	PICO	PRISMA	Theory-	LOE: I
Effect of cervical cancerPurpose: To evaluate the 	(Musa et al.,		Meta-analysis		education	"What is the	Polling effect:	based	
cervical cancer education and provider in of CCS ratesTo evaluate the effect of CC education and PE on CCS ratesseveral countries: Australia, Belgium, Canada, Finland, France, Germany, Italy, Japan, Kenya, and meta- analysisinterventions recommendation for CS ratesManager softwares softwarepublished SR protocolWeaknesses: No scoondary outcome datarecommendati tion for screening rates: A SR and meta- analysisCCS rates (CR, 246, statistic.Published SR protocolWeaknesses: No scoondary outcome datarecommendation analysisOCS ratesProvider recommendation nsCCS rates (CS?"Manager softwares softwarepublished SR protocolV2: Provider rates: A SR and meta- analysisTaiwan, Thailand, and USA2. Provider recommendation nsCCS rates recommendation nsManager softwares softwares softwareFunding: Grant #D43TW00CS frogramsSample Demographics: WomenDV: Participation in CCS programsPorticipation cCS programsStatistical recommendation nsStatistical estimates of interventionsF&A pt populationFunding: Grant #D43TW00Cost rates rates in womenNoreNoreNoreStatistical recommendation nsStatistical estimates of interventionsStatistical estimates of interventionsF&A pt populationFunding: Grant #D43TW00Cost rates recommendation recommendation recommendation cost rates in womenStatistical<	2017).			Setting: Studies	Theory-based	effect of CC		educational	Strengths: Comprehensive
cancer education and providereffect of CC education and PE on CCS ratesAustralia, Belgium, Canada, Finand, France, Germany, Italy, Japan, Kenya, mets: A SR analysisI. CC educationwomen population education CCS?"software increased CCS?"significantly increased CCS?"Weaknesses: No secondary outcome datascreening rates: A SR analysisOn CS rates Mexico, Sweden, Taiwan, Thailand, and USA2. Provider recommendatio nCCS?"Heterogeneity: Statistic.Use of theory-based of education interventionsFunding: Grant #D43TW00SampleSample Demographics: WomenDV: Population raticipation in CCS programsDV: population estimates of tinterventionsStatistical estimates of interventionsStatistical estimates of interventionsF&A pt. population: recommendatio no sFunding: Grant #D43TW00 9575 from Center and Center and Cancer InstituteInclusion Criteria: RCT, & quasi- experimental designsDV: population concers population concersStatistical estimates of interventionsF&A pt. population: The interventions dentified in indeveloped and cCS rotes of Clo (OR = bias: funnel plots generated bias: funnelsoftware software software softwaresoftware software software softwaresoftware software so			Purpose:	were chosen from	CC education		Review	intervention	search, study guided by a
education and provider recommendatio for d screening on screening rates: A SR and meta- analysiseducation education and PE on CCS ratesBelgium, Canada, Finland, France, Germany, Italy, Japan, Kenya, Malaysia, mates: A SR and meta- analysiseducation increased CCS ratesincreased CCS ratesWeaknesses: No secondary outcome data (CR, 2.46, 95% CI: 1.88, 3.21) self- <td>cervical</td> <td></td> <td>To evaluate the</td> <td>several countries:</td> <td>interventions</td> <td>CCS rates in</td> <td>Manager</td> <td>s</td> <td>published SR protocol</td>	cervical		To evaluate the	several countries:	interventions	CCS rates in	Manager	s	published SR protocol
and provider recommendation for CCS ratesFinland, France, Germany, Italy, 	cancer		effect of CC	Australia,	1. CC	women	software	significantly	
recommenda tion for screening rates: A SR and meta- analysisGermany, Italy, Japan, Kenya, Malaysia, Masico, Sweden, Taiwan, Thailand, and USA2. Provider recommendatio nCCS?"Higgins I² statistic.(OR, 2.46, statistic.Ocnelusions: SR suppor the use of theory-based of education interventionsrates: A SR and meta- analysisMalaysia, manysisNN"What is the effect of for CCS on CCS recommendation nsGraphic topoulation statisticalSample populationConclusions: SR suppor the use of theory-based of education interventionsFunding: Grant #D43TW00Sample Demographics: WomenDV: Participation in cCS programsStatistical cS programstesting testin womenF&A pt. population eligible for CCS?"Hingins I² statisticalCORclusions: SR suppor the use of theory-based of education interventionsS75 from NIH Fogarty International Cancer InstituteInclusion experimental designsDV: patisition: N/ADV: populationStatistical estimates of interventionstesting testin womentesting testin womentesting estimates of interventionstesting topoulationtesting testin womentesting testin womentesting <br< td=""><td>education</td><td></td><td>education and PE</td><td>Belgium, Canada,</td><td>education</td><td>population</td><td></td><td>increased</td><td>Weaknesses: No</td></br<>	education		education and PE	Belgium, Canada,	education	population		increased	Weaknesses: No
tion for screening on screening rates: A SR and meta- analysisJapan, Kenya, Malaysia, Mexico, Sweden, Taiwan, Thailand, analysisrecommendation nstatistic.95% CI: 1.88, 3.21) self- sampling for Human Papillomavir us (HPV)Conclusions: SR suppor the use of theory-based G education interventionsFunding: Grant #D43TW00 9575 from NIH Fogarty International Center and the National Cancer InstituteSample Demographics: WomenDV: Participation in CCS programsW: Participation in CCS programsStatistical recommendation nsStatistical estimates of interventionsF&A pt. population: The interventions data developing countries. Th information is limited to CC education only.Bias: NoneMaaysia, Mexico, Sweden, Taiwan, Thailand, analysisRenya, Mexico, Sweden, Taiwan, Thailand, analysisrecommendation ns"What is the effect of provider recommendation nsGraphic self- sampling for Human Papillomavir us (HPV)Conclusions: SR suppor the use of theory-based G education interventionsFunding: Grant #D43TW00 9575 from International Center and the National Center and He National Cancer InstituteDV: Population: N/APopulation Statistical education interventionsF&A pt. population the meta- concers of did (OR = hiss: funnel plots generated by RevMan 5.3Bias: NoneAttrition: N/AHe National concersConcers concers concers concers concers concersConcers concers concers concers concers concers conc	and provider		on CCS rates	Finland, France,			Heterogeneity:	CCS rates	secondary outcome data
screening on screening rates: A SR and meta- analysisMalaysia, Mexico, Sweden, Taiwan, Thailand, and USAn"What is the effect of provider recommendation nsI.88, 3.21)Conclusions: SR suppor the use of theory-based of education interventionsFunding: Grant #D43TW00Sample Demographics: WomenIV2: Provider recommendation nsIV2: Provider recommendation nsGraphic display: Relevant forest populationSampling for Human Papillomavir us (HPV)F&AFunding: Grant #D43TW00Demographics: WomenDV: Participation in CCS programsDV: Populationpopulation eligible for CCS?"Statistical estimates of interventionsF&AFunding: Grant #D43TW00Criteria: RCT, cluster RCT, & quasi- experimental designsDV: Participation in Cluster RCT, & cluster RCT, & cluster RCT, with the National Cancer InstituteNANAStatistical estimates of interventionsF&ABias: NoneAttrition: N/AAttrition: N/ANAStatistical estimatesconclusion: cluster RCT, and	recommenda			Germany, Italy,	2. Provider	CCS?"	Higgins I ²	(OR, 2.46,	
screening rates: A SR and meta- analysisMexico, Sweden, Taiwan, Thailand, and USAIV2: Provider recommendation nseffect of providerGraphic display: Relevant forest plotsthe use of theory-based of education interventionsFunding: Grant #D43TW00 9575 from NIH Fogarty International Center and the National Cancer InstituteDV: population Participation in cluster RCT, & quasi- experimental designsDV: population estimates of cCS programsGraphic provider recommendation nsGraphic provider recommendation populationSelf- sampling for Human Papillomavir us (HPV) testing estimates of interventionsthe use of theory-based of education interventionsFunding: Grant #D43TW00 9575 from NIH Fogarty International Center and the National Cancer InstituteDV: population Participation in cluster RCT, & quasi- experimental designsDV: population experimental designsStatistical estimates of interventionsself- sampling for Human Papillomavir us (HPV) testing enterventionsHe use of theory-based of education interventionsBias: NoneMexico, Sweden, Taiwan, Thailand, and USAIV2: Provider recommendation nsGraphic provider recommendation nsGraphic provider recommendation nsGraphic display: meta-analysisHuman plots estimates of interventionsF&AFwa Publication plots generated plots generated plots generated by RevMan 5.3CC education only.CC education only.Bias: None <td>tion for</td> <td></td> <td></td> <td>Japan, Kenya,</td> <td>recommendatio</td> <td></td> <td>statistic.</td> <td>95% CI:</td> <td></td>	tion for			Japan, Kenya,	recommendatio		statistic.	95% CI:	
rates: A SR and meta- analysisTaiwan, Thailand, and USAIV2: Provider recommendation nsprovider recommendation for CCS on CCS rates in womendisplay: Relevant forest plotssampling for Human Papillomavir us (HPV)education interventionsFunding: Grant #D43TW00Sample Demographics: WomenDV: Participation in CCS programsprovider recommendation nsdisplay: Relevant forest plotssampling for Human Papillomavir us (HPV)education interventions9575 from NIH Fogarty International Cancer InstituteInclusion quasi- experimental designsDV: Participation in CCS programsStatistical cCS ?"sampling for Relevant forest plotseducation interventions for CCS on CCS statisticalsampling for Human Papillomavir us (HPV)education interventions for developed and developing countries. The information is limited to CC: 1.32, Publication bias: flunnel plots generated by RevMan 5.3sampling for Human Papillomavir us (HPV)education interventions for CCS on CCS the meta-analysis can be cCS?"Bias: NoneTaiwan, Thailand, and USAIV2: Provider recommendation nsprovider recommendation for CCS on CCS CCS?"sampling for Human testing tinterventionseducation interventions testing tinterventionsFunding: drateTraition: N/AIV2: Provider recommendation in CCSprovider recommendation testing testing testing testing testingsampling for testing testing testing testingeducation interventi	screening on			Malaysia,	n	"What is the		1.88, 3.21)	Conclusions: SR supports
and meta- analysisand USArecommendation nsrecommendation for CCS on CCS rates in womenRelevant forest plotsHumanPapillomavir us (HPV)F&AFunding: Grant #D43TW00Demographics: WomenDV: Participation in CCS programspopulationStatisticaltesting estimates of increasedtesting interventions identified in the meta-analysis can be applicable to CC education9575 from NIH Fogarty International Cancer InstituteInclusion Criteria: RCT, cluster RCT, & quasi- experimental designsCriteria: RCT, cluster RCT, & estimates of cluster RCT, & cluster RCT, & estimational CancerNIH Fogarty (CI: 1.32, PublicationBias: NoneHuman populationF&ABias: NoneMather meta-Attrition: N/AFecommendation nsFecommendation for CCS on CCS rates in women plots generated by RevMan 5.3Human plotsF&ABias: NoneFunding: meta-Facommendation plotsFecommendation plotsRelevant forest plotsHuman plotsF&ABias: NoneFunding: meta-Facommendation plotsFecommendation plotsFecommendation plotsFecommendation plotsFecommendation plotsFecommendation plotsFecommendation plotsFecommendation plotsFecommendation plotsFecommendation plotsFecommendation plotsFecommendation plotsFecommendation plotsFecommendation plotsFecommendation plotsFecommendation plotsFecommendation plotsFecomme	screening								the use of theory-based CC
analysisnsfor CCS on CCS rates in women population eligible for CCS programsplotsPapillomavir us (HPV) testing increased CCS rates by nearly2- fold (OR = 1.71, 95%F&AFunding: Grant #D43TW00 9575 from NIH Fogarty International Center and Cacer InstituteInclusion Criteria: RCT, cluster RCT, & quasi- experimental designsNineFor CCS on CCS rates in women population eligible for CCS?"PlotsPapillomavir us (HPV) testing increased CCS rates by nearly2- fold (OR = 1.71, 95% CC education only.For the meta-analysis can be applicable to CC education of developing countries. The information is limited to CC education only.Bias: NoneKatrition: N/ANaNaPublication bias: funnel plots generated by RevMan 5.3Papillomavir us (HPV) testing increased CCS rates by nearly2- fold (OR = 1.71, 95% CC education only.Papillomavir testing increased CC education only.	rates: A SR			Taiwan, Thailand,	IV2: Provider	provider		sampling for	education interventions
Funding: Grant #D43TW00 9575 from NIH Fogarty International Cancer InstituteSample Demographics: WomenDV: Participation in CCS programsrates in women population eligible for CCS?"is (HPV) testing increased CCS rates by nearly 2- fold (OR = 1.71, 95% CI: 1.32, 2.22pt. population: The interventions identified in the meta-analysis can be applicable to CC education in developed and developing countries. The information is limited to CC education only.Bias: NoneMater LowAttrition: N/ANAAttrition: N/ANAAttrition: N/A	and meta-			and USA	recommendatio		Relevant forest		
Funding: Grant #D43TW00 9575 from NIH Fogarty International Cancer InstituteDemographics: WomenDV: Participation in CCS programspopulation eligible for CCS?"Statistical estimates of increased OR and random effects models not CI: 1.32, Publication bias: funnel plots generated by RevMan 5.3interventions identified in the meta-analysis can be applicable to CC education ind eveloped and developing countries. The information is limited to CC education only.Bias: NoneDemographics: WomenDV: Participation in CCS programspopulation eligible for CCS?"Statistical estimates of increased OR and random effects models neta-analysisinterventions identified in the meta-analysis can be applicable to CC education in developed and developing countries. The information is limited to CC education only.Bias: NoneAttrition: N/AAttrition: N/AInterventionsCCS artes Publication bias: funnel plots generated by RevMan 5.3interventions identified in the meta-analysis can be applicable to CC education of CCS and the meta-analysisBias: NoneInterventionsInterventionsCCS artes fold (OR = 1.71, 95% DistributeCC education only.	analysis				ns	for CCS on CCS	plots	Papillomavir	F&A
Grant #D43TW00 9575 fromWomenParticipation in CCS programsestimates of interventionsincreased CCS rates oR and random by nearly 2- by nearly 2- in developed andthe meta-analysis can be applicable to CC educati in developed and developing countries. Th information is limited to CI: 1.32, 2.22NIH Fogarty International Center and Cancer InstituteInclusion Criteria: RCT, eluster RCT, & quasi- experimental designsInclusion Criteria: RCT, eluster RCT, & experimental designsInclusion CCS programsIncreased cCS ?"the meta-analysis can be applicable to CC educati in developed and developing countries. Th information is limited to CI: 1.32, 2.22the meta-analysis can be applicable to CC education in developed and developing countries. Th information is limited to CI: 1.32, 2.22Bias: NoneAttrition: N/AInclusion AInclusion Attrition: N/AInclusion AInclusion CS programsIncreased CCS ?"Increased concer bias: funnel plots generated by RevMan 5.3the meta-analysis can be applicable to CC education only.				Sample		rates in women		us (HPV)	
#D43TW00 9575 from NIH Fogarty International Center and the National Cancer InstituteInclusion Criteria: RCT, cluster RCT, & quasi- experimental designsCCS programsCCS?"interventions OR and random effects models meta-analysisapplicable to CC educati in developed and developing countries. The information is limited to CC education only.Bias: NoneKatrition: N/AAttrition: N/ACCS programsCCS?"interventions OR and random effects models meta-analysisCCS rates by nearly 2- fold (OR = 1.71, 95% C.I: 1.32, 2.22applicable to CC educati in developed and developing countries. The information is limited to CC education only.	Funding:			Demographics:	DV:	· · ·	Statistical		interventions identified in
9575 from NIH Fogarty InternationalInclusion Criteria: RCT, cluster RCT, & quasi- experimental designsOR and random effects models meta-analysisby nearly 2- fold (OR = 1.71, 95% CI: 1.32, 2.22in developed and developing countries. Th information is limited to CC education only.9575 from NIH Fogarty InternationalInclusion Criteria: RCT, cluster RCT, & quasi- experimental designsOR and random effects models to CI: 1.32, 2.22by nearly 2- fold (OR = 1.71, 95% CI: 1.32, 2.22in developed and developing countries. Th information is limited to CC education only.Publication bias: funnel plots generated by RevMan 5.32.22CC education only.	Grant			Women	-		estimates of		-
NIH Fogarty International Center and Center and Cancer InstituteCriteria: RCT, cluster RCT, & quasi- experimental designseffects models meta-analysisfold (OR = 1.71, 95% CI: 1.32, 2.22developing countries. The information is limited to CC education only.NIH Fogarty International Center and Cancer Instituteexperimental designsexperimental designsexperimental bias: funnel plots generated by RevMan 5.3fold (OR = 1.71, 95% CI: 1.32, 2.22developing countries. The information is limited to CC education only.Bias: NoneAttrition: N/AAttrition: N/Ainformation is limited to and by RevMan 5.3information is limited to countries.					CCS programs	CCS?"			applicable to CC education
International Center and the National Cancer Institutecluster RCT, & quasi- experimental designsmeta-analysis1.71, 95% CI: 1.32, Dublicationinformation is limited to CC education only.InstituteAttrition: N/AAttrition: N/APublication bias: funnel plots generated by RevMan 5.32.22							OR and random		
Center and the National Cancer Institute quasi- experimental designs quasi- experimental designs Publication bias: funnel plots generated by RevMan 5.3 CI: 1.32, 2.22 CC education only. Bias: None Attrition: N/A Publication bias: funnel plots generated by RevMan 5.3 CI: 1.32, 2.22 CC education only.	NIH Fogarty						effects models		developing countries. This
the National experimental Publication 2.22 Cancer designs bias: funnel plots generated Institute Attrition: N/A Publication 2.22	International			-			meta-analysis		
Cancer designs bias: funnel Institute Attrition: N/A plots generated Bias: None bias: funnel plots generated	Center and							CI: 1.32,	CC education only.
Institute Bias: None Attrition: N/A Bias: None	the National			experimental			Publication	2.22	
Bias: None Attrition: N/A by RevMan 5.3	Cancer			designs			bias: funnel		
Bias: None	Institute								
				Attrition: N/A			by RevMan 5.3		
recognized	recognized								

Country: USA								
Citation	Conceptual Framework	Design/Method	Sample/Setting	Major Variables & Definitions	Measurement	Analysis	Findings	Decision for Use
Citation (Atere- Roberts et al., 2020). Intervention s to increase breast and cervical cancer screening uptake among rural women: a scoping review Funding: None stated Bias: None stated Country: USA	SCF	Design: SR Purpose: To review literature for interventions to increase BCC screening	N: 8 Setting: USA Sample Demographics: RW Inclusion Criteria: Peer- reviewed journal, English, published January 2006 to October 2019, provided intervention for cervical or breast cancer, reported outcome data, Attrition: N/A	Interventions include PN strategies, educational outreach programs, peer counseling, and small media initiatives	Scoping review of PubMed to identify BCC screening interviews conducted in rural settings	PRISMA	Group Education: English speaking Latina women showed decreased CCS odd (OR 0.66 (0.47-0.92) Spanish speaking Latina women showed increased odds (OR 1.64 (1.22- 2.20) One on One Education: Increased CCS w/individual lay health	 LOE: I Strengths: First study to focus on BCC interventions in rural populations Weaknesses: Search restricted to PubMed, strict inclusion criteria Conclusions: This study reviewed literature that may help promote the development of BCC interventions F&A pt. population: Limited feasibility. Applicable to rural communities in the USA for BCC interventions

Three large scalePurpose: To describe predictors of CC underscreening of cervical cancerHINTS: n=745 HCPC: n=1,573predictorsBRFSS – telephone survey by each state's health departmentlikely to receive CCSresults from 3 large national surveysSample Demographics: underscreening age in the United StatesSetting: USADV: CCSby each state's health departmentWeaknesses: Differen survey years, self-repo responses, different sampling frames, diffe guestionnaireUnited StatesInclusion Criteria: women, MA 45-65, withoutHINTS - questionnaireHINTS - cone on one interviewInclusion criteria: women, MA 45-65, withoutConclusions: CCS for older women is below								education (OR 1.70; 1.31, 2.221) Multicomp onent Education: No significant changes noted	
(Harper et al., 2020). Three large scaleHPDPTNational Health Surveyswomen & BRFSS: n=41,747 HINTS: n=745 HCPC: n=1,573SurveysMultivariate Analysislocations were less likely to receive CCSStrengths: Description results from 3 large national surveysscale scale scale highlight the complexity of cervical cancer underscreening mg among women 45- 65Purpose: To describe predictors of CC underscreening in women 46-65Setting: USASurveysMultivariate 	Citation	-	Design/Method	Sample/Setting	Variables &	Measurement	Analysis	Findings	Decision for Use
	(Harper et al., 2020). Three large scale surveys highlight the complexity of cervical cancer underscreeni ng among women 45- 65 years of age in the United States		National Health Surveys Purpose: To describe predictors of CC underscreening	BRFSS: n=41,747 HINTS: n=745 HCPC: n=1,573 Setting: USA Sample Demographics: Women, ages 45- 65 Inclusion Criteria: women, MA 45-65,	IV: Elderly women & socioeconomic predictors	Surveys BRFSS – telephone survey by each state's health department HINTS – questionnaire HCPC – one on	Multivariate	locations were less likely to	Strengths: Description of results from 3 large national surveys Weaknesses: Different survey years, self-reported responses, different sampling frames, different survey sample sizes, changing professional guidelines; limited

Michigan Institute for Clinical and Health Research UL1TR0022 40 & The University of Michigan Rogel Cancer Center P30CA0465 92 grants Bias: None stated Country: USA								F&A pt. population: The analysis applies to women ages 45-65 across the USA.
Citation	Conceptual Framework	Design/Method	Sample/Setting	Major Variables & Definitions	Measurement	Analysis	Findings	Decision for Use
Citation (Liu et al., 2017).	Inferred HPDPT	Design: XSS Purpose: To	N: 420 Setting: 4	IV: Attitudes & knowledge about CC	Face-to-face interviews using questionnaires	Binary logistic regression	Majority of participants had positive	LOE: V Strengths: None stated
Assessing		assess	counties of Jining	about CC	with trained		attitudes	Strengths. None stated
knowledge		knowledge and		DV: CCS	interviewers		towards	Weaknesses: Not
and attitudes		attitude towards	Sample				CCS	generalizable,
towards		CC and	Demographics:				UC	questionnaire used only
cervical cancer		screening among rural women	Women, 30-65yo				HC providers	analyzed quantitative data, not qualitative
screening		Tutal women					impact	not quantative

among rural women in eastern China Funding: None stated Bias: None stated Country: China			Inclusion Criteria: Women, MA 30-65, without hysterectomy, sexually active Attrition: 15				health promotion of CCS Age, level of income, and education impact knowledge of CC	Conclusions: Overall positive attitude towards CC, but limited knowledge on CCS F&A pt. population: Not generalizable, specific to the 4 counties of Jining
Citation	Conceptual Framework	Design/Method	Sample/Setting	Major Variables & Definitions	Measurement	Analysis	Findings	Decision for Use
Citation (Megersa et al., 2020) Community cervical cancer screening:	HBM	Design: QS Purpose: To explore barriers to self-sampling CCS	N: 47 Setting: University of Gondar Sample	IV: Barriers to HPV self- samplingDV: HPV self- sampling rates	IDI, FGD	Audio recorded data transcribed, thematic analysis	Lack of knowledge about CC Common barriers to self-	LOE: VI Strengths: Identified screening barriers Weaknesses: Men's opinion was not evaluated;
Barriers to successful home-based HPV self- sampling in			Demographics: Women, MA 28- 40, primarily married, uneducated				sampling HPV: lack of education, perceived	study was conducted 2 years after the pilot study

Dabat district, North Gondar, Ethiopia. A qualitative study Funding: Open Society Foundation; Baden- Wu"rttember g Ministry of Science; Research and the Arts; Ruprecht- Karls- Universita"t Heidelberg Bias: None stated Country: Ethiopia	Concentual	Design/Method	Inclusion Criteria: Women who had participated in a home-based HPV sampling pilot study Attrition: None stated	Major	Massurament	Analysis	healthy status, social influence, husband disapproval, religion	Conclusions: This study identified additional barriers to self-sampling F&A pt. population: Feasible to the hospital setting at the University of Gondar due to specific women socioeconomic factors
Citation	Conceptual Framework	Design/Method	Sample/Setting	Major Variables & Definitions	Measurement	Analysis	Findings	Decision for Use
Citation	Inferred	Design: Intake	N: 524	IV: SB	10-item	Descriptive &	Education	LOE: V
	HPDPT	survey & 10-			questionnaire –	Multivariate	attainment	

	T.			T	T		
(Akinlotan	item true/false	Setting: 17	DV: CC risk	true/false to		inversely	Strengths: None stated
et al., 2017).	questionnaire	counties in Texas	knowledge	determine CC	Chi Square	correlates	
Cervical	-		_	risk factor		with risk	Weaknesses:
cancer	Purpose: To	Sample		knowledge		knowledge	Questionnaire was given to
screening	identify	Demographics:					women already presenting
barriers and	correlations	uninsured women,		10-item		3.2% of	for CCS
risk factor	between CC risk	race/ethnicity:		questionnaire		participants	
knowledge	factor knowledge	Black, non-		with Likert scale		unaware of	Conclusions: Study
among	and examine SB	Hispanic white,		to measure		any CC risk	highlights level of
uninsured	to screening	Hispanic		patient's		factors	awareness of CC risk
women	among a group	1		perceived			factors
	of low-income	Inclusion		barriers		70% of	
Funding:	uninsured	Criteria: Women				participants	F&A
Cancer	women	with income				knew CC	pt. population: The
Prevention		below 250% PL,				correlated	surveys in this study could
and		21 or older,				w/sexual	be utilized for all women
Research		without				activity	to evaluate CC risk
Institute of		hysterectomy				uctivity	knowledge
Texas		nystereetonry				60% knew	Kilowieuge
(Grant #		Attrition: 145				CC risk	
(Grant // PP130090)						correlated	
11150070)						w/multiple	
Bias: None						sex partners	
stated						sex partitiers	
stated						64.4% knew	
Country:						CC risk	
USA						correlated	
USA						w/being	
						immunocom	
						promised	
						Omly, 90/	
						Only 8%	
						knew all risk	

							factors for CC	
Citation	Conceptual Framework	Design/Method	Sample/Setting	Major Variables & Definitions	Measurement	Analysis	Findings	Decision for Use
Citation (Barrington et al., 2019). Patient navigator reported patient barriers and delivered activities in two large federally- funded cancer screening programs Funding: None stated Bias: None stated Country: USA	Inferred HPDPT	Design: XSS Purpose: Characterize PNs within NBCCEDP & CRCCP Collect data directly from PN's within federally funded screening programs	N: 582 n: 410 breast & cervical n: 172 colorectal Setting: PN's working for NBCCEDP or CRCCP Sample Demographics: majority female, college education, English, heterosexual, health professional Inclusion Criteria: PN's working for NBCCEDP or CRCCP Attrition: None stated	IV: PN DV: Perceived patient barriers	Online survey	Descriptive statistics z-statistic	Common patient barriers identified were related to SB. Unique findings from PN's included patient transportatio n and scheduling	LOE: V Strengths: Data from a large nationally represented navigator Weaknesses: Low response to survey Conclusions: Common SB identified by PN's. F&A pt. population: Feasible in rural and underserved communities due to similar SB identified

Table A2

Synthesis Table

Study Characteristics	Yan et al.	Binka et al.	Weng et al.	Musa et al.	Atere- Roberts et al.	Harper et al.	Liu et al.	Megers a et al.	Akinlotan et al.	Barringto n et al.
Year	2019	2019	2020	2017	2020	2020	2017	2020	2017	2019
XSS			•				•			•
SR				•	•					
QS	•	•						•		
Survey						•			•	
# Participants	39	55	1483	28	8	44,065	420	47	524	582
Theory	Inferred HPDPT	Socioecologica l Model of McLeroy et al.	Inferred HPDPT	SCF & SEM	SCF	Inferred HPDPT	Inferred HPDPT	HBM	Inferred HPDPT	Inferred HPDPT
Measurement Tools	IDI, Questionnaire , FGD	IDI, FGD	Questionnair e 3 close- ended questions, 14 close-ended questions	PIC O	Scoping review of PubMe d	3 Nationa 1 Health Surveys	Face-to- face interview s	IDI, FGD	10-item questionnair e true/false & Likert	Online survey
Country	China	Ghana	China	USA	USA	USA	China	Ethiopi a	USA	USA
Demographics										
Mean Age	48	30-65	32.86	N/A	N/A	45-65	30-65	28-40	21<	<40
Independent Variables										

Vnowladaa of	_						-			
Knowledge of	•						•			
CC										
Barriers to CC	•	•								
Factors			•							
associated										
w/screening										
CC education				•	•					
Provider				•						
recommendatio										
n										
Peer counseling					•					
Small media					•					
initiatives										
Socioeconomic						•				
predictors										
Elderly women						•				
PN					•					•
SB									•	
Barriers to HPV								•		
self-sampling										
Dependent										
Variables										
CCS rates	•	•	•		•		•			
CCS treatment		•								
Participation in				•						
CCS programs										


HPV self-							•		
sampling rates									
CC risk knowledge								•	
Perceived									•
patient barriers									
Findings									
Gap in CC	•		•					•	
knowledge &									
health awareness									
Fear of CC &	•								
screening	•								
outcomes									
Cultural barriers	•								
Social influence	•		•				•		
Inconvenience	•								
Organizational		•							
barriers									
Education				•			•	•	
increased CCS rates									
Self-sampling				•			•		
HPV increases							•		
CCS rates									
Group					•				
education									

increases CCS rates							
One on one education increases CCS rates			•				
Multicomponen t education does not impact CCS rates			•				
Elderly RW have decreased CCS rates				•			
Positive attitude towards CCS					•		
HC providers positively impact CCS rates					•		
SB correlate w/CC knowledge					•		•

Appendix B

Figure 1


Social Cognitive Theory



Vancouver et al. (2002).

Figure 2

Lean Sigma Six Model



Rastogi (2021).

Appendix C

Written Informed Consent

Socioeconomic Barriers in Rural Women and Cervical Cancer Screening: A Gap Analysis

I am a graduate student under the direction of Dr. Patricia Janicek in the Women's Health Nurse Practitioner program in the Edson College of Nursing and Health Innovation at Arizona State University. I am conducting a research study to identify socioeconomic barriers in rural women that prevent routine cervical cancer screening.

I am inviting your participation, which will involve 20 to 30 minutes in completing a survey that identifies demographic information, basic cervical cancer knowledge, and perceived barriers to routine cervical cancer screening. You have the right not to answer any question, and to stop participation at any time.

Your participation in this study is voluntary. If you choose not to participate or to withdraw from the study at any time, there will be no penalty. You must be 21 or older to participate in this study.

Your responses to the survey will be used to identify socioeconomic barriers that impact routine cervical cancer screening which can lead to the development of interventions to overcome the identified socioeconomic barriers. There are no foreseeable risks or discomforts to your participation.

Your responses will be anonymous and no identifiable participant information will be collected. The results of this study may be used in reports, presentations, or publications but your name will not be used.

If you have any questions concerning the research study, please contact the research team at: <a href="https://www.ltps.org/littorial.org/litt

Appendix D

Project Survey

As of today, how many people live in your house					
Insurance status: Uninsured Medicare		Private Insura	nce		
What is your family yearly income ?					
What is your county of residence?					
] Mohave Nav	/ajo	
		ta Cruz 🗌 Yav			
	lease specify)	:			
Sex: 🗌 Male 🗌 Female	_	_			
		English	/Spanish		
What is your home address' zip code?		_			
What is your current marital status? (Please chec				ing with par	tner
What is the highest level of education you <u>compl</u>	_		·		
None Kindergarten Middle School	High School	Vocationa	College Colle	ege 🗌 Grad	luate school
Are you Hispanic or Latino? Yes	lo 🗌	Don't know/N	ot sure 🗌 Pref	er not to ans	swer
Which of the following would you say best descri	ibes your race	?			
American Indian or Alaskan Native	sian	Black or Africa	n American		
Native Hawaiian or other Pacific Islander 🗌 V	Vhite or Cauca	asian 🗌 Other	(please specify): _		
How did you first hear about our screening progr	ram?				
Community event Physician/health care	provider	Family mem	ber/friend		
Other (please specify):					
Do you have a regular doctor or healthcare provi	ider?	Yes	No		
When was the last time you visited your healthca	are provider?	<6 mor	nths 🗌 6 months	-1 year 🛛>	1 year
When you visit your doctor or healthcare provid	ler, how ofter	n do you do the	e following (pleas	e circle):	
	Never	Rarely	Sometimes	Often	
Prepare a list of questions for your doctor	1	2	2	4	Always
		Z	3	4	Always 5
Ask questions about the things you want		Z	3	4	
Ask questions about the things you want to know and things you don't understand		Z	3	4	
Ask questions about the things you want to know and things you don't understand about your treatment	1	2	3	4	
to know and things you don't understand about your treatment	1	_	-	-	5
to know and things you don't understand about your treatment Discuss any personal problems that may be	1	_	-	-	5
to know and things you don't understand about your treatment Discuss any personal problems that may be related to your illness		2	3	4	5
to know and things you don't understand about your treatment Discuss any personal problems that may be		2	3	4	5
to know and things you don't understand about your treatment Discuss any personal problems that may be related to your illness How confident are you filling out	1	2 2 2	3	4	5 5 5
to know and things you don't understand about your treatment Discuss any personal problems that may be related to your illness How confident are you filling out medical forms by yourself?	1 1 ease check oni	2 2 2	3	4	5 5 5
to know and things you don't understand about your treatment Discuss any personal problems that may be related to your illness How confident are you filling out medical forms by yourself? Would you say that in general your health is: (<i>Ple</i>	1 1 ease check oni Fair [2 2 2 2 y one). Poor	3 3 3	4 4 4	5 5 5

Now thinking about your mental health, which includes stress, depression, and problems with emotions, for how many days during the past <u>30 days</u> was your mental health not good? _____Days.

"A pap test is a procedure where a physician scrapes for cells from the cervix or vagina to check for cervical or vaginal cancer. If you have had a hysterectomy to remove the uterus, you no longer need a pap test." Have you had a hysterectomy? Yes No Not sure If answer is no, skip to T/F questions. When was your last pap test Never had Within past 1 year 1-2 years >2years Not sure Have you ever had an abnormal result from a pap test? Yes No Not sure Did a doctor or healthcare provider refer you here today? Yes No Who referred you here today? Self Doctor/health care provider Other Name of clinic or agency/organization name if applicable:
"We want to know what you know now, so we can figure out how best to help you with information."
At what age should people start having a pap test? <i>"Please answer True or False to the following statements: A woman is more likely to have cervical cancer if"</i>
she has had many sexual partners.
she smokes cigarettes.
she started having sex at a young age.
she has unprotected sex.
she does do not go for regular (Pap) smears/tests.
she has a sexually transmitted disease or virus.
she used birth control pills for a long time.
she has many children.
she has a weakened immune system (e.g. because of HIV/AIDS, immunosuppressant drugs
or having a transplant).
it runs in her family.
"In the past, to what extent were the following items barriers (obstacles) to your receiving a pap test ?" (please circle one number for each question):
Strongly Disagree Neither Agree Agree Strongly
Disagree nor disagree Agree
Feelings of embarrassment 1 2 3 4 5
Fear of finding cancer 1 2 3 4 5
Transportation 1 2 3 4 5

Cost	1	2	3	4	5
Anxiety about procedure	1	2	3	4	5
Lack of knowledge	1	2	3	4	5
Lack of time	1	2	3	4	5
Anticipation of pain	1	2	3	4	5
Forgetting to schedule an appointment	1	2	3	4	5
Other health problems	1	2	3	4	5
Language barriers	1	2	3	4	5
Male physician	1	2	3	4	5
Family/Personal History					
Have you or any member of your family (r	nother, sis	ter, daughters)	had cervical c	ancer?	
				🗌 True 🗌 Fa	lse 🗌 Not sure
Are you aware that there is a 3-part vaccir	ne that car	n protect agains	st most forms o	of cervical cance	er
If yes, have you ever received an HPV vaco	cine? 🗌 Y	es 🗌 No 🛛	Not sure		
If yes, was the 3-part series completed?	Y	es 🗌 No 🛛 [Not sure		

Appendix E

2021 NBCCEDP Allowable Procedures and Relevant CPT Codes

	v are allowable procedures and the corresponding suggested Current Procedural Tern cer Early Detection Program (NBCCEDP) under these general conditions:	ninology	(CPT) codes for u	use in the Nation	nal Breast and
man • Whe CDC	ntees are required to be responsible stewards of the NBCCEDP funds and use screenin iner. en questions arise regarding the appropriateness to use a specific CPT code, the grant to determine appropriateness. CPT codes listed are not all-inclusive and grantees may add other, including temporar	ee shou	ld discuss with th	eir local medica	l consultants and
CPT Code	Office Visits	End Note	Professional Component (-26)	Technical Component (-TC)	Total
G2025	Telehealth visit.				\$ 99.45
99202	New patient; medically appropriate history/exam; straightforward decision making; 15-29 minutes.				\$ 71.64
99203	New patient; medically appropriate history/exam; low level decision making; 30- 44 minutes.				\$ 110.42
99204	New patient; medically appropriate history/exam; moderate level decision making; 45-59 minutes.	1			\$ 165.29
99205	New patient; medically appropriate history/exam; high level decision making; 60- 74 minutes.	1			\$ 218.34
99211	Established patient; evaluation and management, may not require presence of physician; presenting problems are minimal.				\$ 22.18
99212	Established patient; medically appropriate history/exam; straightforward decision making; 10- 19 minutes.				\$ 55.12
99213	Established patient; medically appropriate history/exam; low level decision making; 20-29 minutes.				\$ 89.83
99214	Established patient; medically appropriate history/exam; moderate level decision making; 30-39 minutes.				\$ 127.59

CPT is a registered trademark of the American Medical Association. Revised 05.28.2021

1 | P a g e 1 1

CPT Code	Office Visits	End Note	Professional Component (-26)	Technical Component (-TC)		Total
99385	Initial comprehensive preventive medicine evaluation and management; history, examination, counseling and guidance, risk factor reduction, ordering of appropriate immunizations and lab procedures; 18 to 39 years of age.	2			\$	110.42
99386	Same as 99385, but 40 to 64 years of age.	2			\$	110.42
99387	Same as 99385, but 65 years of age or older.	2			\$	110.42
99395	<i>Periodic</i> comprehensive preventive medicine evaluation and management; history, examination, counseling and guidance, risk factor reduction, ordering of appropriate immunizations and lab procedures; 18 to 39 years of age.	2			\$	89.83
99396	Same as 99395, but 40 to 64 years of age.	2			\$	89.83
99397	Same as 99395, but 65 years of age or older.	2			\$	89.83
CPT Code	Screening and Diagnostic Procedures	End Note	Component	Component		Total
CPT Code	Screening and Diagnostic Procedures		Component (-26)	Component (-TC)		Total
CPT Code Various	Screening and Diagnostic Procedures To include any pre-operative testing procedures medically necessary for the planned surgical procedure (e.g., complete blood count, urinalysis, pregnancy					Total
Various	To include any pre-operative testing procedures medically necessary for the planned surgical procedure (e.g., complete blood count, urinalysis, pregnancy test, pre-operative CXR, etc.).	Note	(-26)	(-тс)		
Various G0279	To include any pre-operative testing procedures medically necessary for the planned surgical procedure (e.g., complete blood count, urinalysis, pregnancy test, pre-operative CXR, etc.). Diagnostic digital breast tomosynthesis, unilateral or bilateral.				\$	53.66
Various	To include any pre-operative testing procedures medically necessary for the planned surgical procedure (e.g., complete blood count, urinalysis, pregnancy test, pre-operative CXR, etc.).	Note	(-26)	(-тс)	\$	
Various G0279	To include any pre-operative testing procedures medically necessary for the planned surgical procedure (e.g., complete blood count, urinalysis, pregnancy test, pre-operative CXR, etc.). Diagnostic digital breast tomosynthesis, unilateral or bilateral.	Note	(-26)	(-тс)	· ·	53.66
Various G0279 10004	To include any pre-operative testing procedures medically necessary for the planned surgical procedure (e.g., complete blood count, urinalysis, pregnancy test, pre-operative CXR, etc.). Diagnostic digital breast tomosynthesis, unilateral or bilateral. Fine needle aspiration biopsy without imaging guidance, each additional lesion.	Note	(-26)	(-тс)	\$	53.66 50.78
Various G0279 10004 10005	To include any pre-operative testing procedures medically necessary for the planned surgical procedure (e.g., complete blood count, urinalysis, pregnancy test, pre-operative CXR, etc.). Diagnostic digital breast tomosynthesis, unilateral or bilateral. Fine needle aspiration biopsy without imaging guidance, each additional lesion. Fine needle aspiration biopsy including ultrasound guidance, first lesion. Fine needle aspiration biopsy including ultrasound guidance, each additional	Note	(-26)	(-тс)	\$	53.66 50.78 134.41
Various G0279 10004 10005 10006	To include any pre-operative testing procedures medically necessary for the planned surgical procedure (e.g., complete blood count, urinalysis, pregnancy test, pre-operative CXR, etc.). Diagnostic digital breast tomosynthesis, unilateral or bilateral. Fine needle aspiration biopsy without imaging guidance, each additional lesion. Fine needle aspiration biopsy including ultrasound guidance, first lesion. Fine needle aspiration biopsy including ultrasound guidance, each additional lesion.	Note	(-26)	(-тс)	\$ \$ \$	53.66 50.78 134.41 60.12
Various G0279 10004 10005 10006 10007	To include any pre-operative testing procedures medically necessary for the planned surgical procedure (e.g., complete blood count, urinalysis, pregnancy test, pre-operative CXR, etc.). Diagnostic digital breast tomosynthesis, unilateral or bilateral. Fine needle aspiration biopsy without imaging guidance, each additional lesion. Fine needle aspiration biopsy including ultrasound guidance, first lesion. Fine needle aspiration biopsy including ultrasound guidance, each additional lesion. Fine needle aspiration biopsy including fluoroscopic guidance, first lesion. Fine needle aspiration biopsy including fluoroscopic guidance, each additional	Note	(-26)	(-тс)	\$ \$ \$ \$	53.66 50.78 134.41 60.12 303.11
Various G0279 10004 10005 10006 10007 10008	To include any pre-operative testing procedures medically necessary for the planned surgical procedure (e.g., complete blood count, urinalysis, pregnancy test, pre-operative CXR, etc.). Diagnostic digital breast tomosynthesis, unilateral or bilateral. Fine needle aspiration biopsy without imaging guidance, each additional lesion. Fine needle aspiration biopsy including ultrasound guidance, first lesion. Fine needle aspiration biopsy including ultrasound guidance, each additional lesion. Fine needle aspiration biopsy including fluoroscopic guidance, first lesion. Fine needle aspiration biopsy including fluoroscopic guidance, each additional lesion.	Note	(-26)	(-тс)	\$ \$ \$ \$ \$	53.66 50.78 134.41 60.12 303.11 161.27

CPT is a registered trademark of the American Medical Association. Revised 05.28.2021

CPT Code	Screening and Diagnostic Procedures	End Note	Professional Component (-26)	Technical Component (-TC)		Total
10012	Fine needle aspiration biopsy including MRI guidance, each additional lesion.	8			\$	275.10
10021	Fine needle aspiration biopsy without imaging guidance, first lesion.				\$	101.52
19000	Puncture aspiration of cyst of breast.				\$	106.27
19001	Puncture aspiration of cyst of breast, each additional cyst, used with 19000.				\$	26.77
19081	Breast biopsy, with placement of localization device and imaging of biopsy specimen, percutaneous; stereotactic guidance; first lesion.	6			\$	564.38
19082	Breast biopsy, with placement of localization device and imaging of biopsy specimen, percutaneous; stereotactic guidance; each additional lesion.	6			\$	450.60
19083	Breast biopsy, with placement of localization device and imaging of biopsy specimen, percutaneous; ultrasound guidance; first lesion.	6			\$	564.72
19084	Breast biopsy, with placement of localization device and imaging of biopsy specimen, percutaneous; ultrasound guidance; each additional lesion.	6			\$	442.50
19085	Breast biopsy, with placement of localization device and imaging of biopsy specimen, percutaneous; magnetic resonance guidance; first lesion.	6			\$	866.35
19086	Breast biopsy, with placement of localization device and imaging of biopsy specimen, percutaneous; magnetic resonance guidance; each additional lesion.	6			\$	684.87
19100	Breast biopsy, percutaneous, needle core, not using imaging guidance.				\$	156.49
19101	Breast biopsy, open, incisional.				\$	340.24
19120	Excision of cyst, fibroadenoma or other benign or malignant tumor, aberrant breast tissue, duct lesion, nipple or areolar lesion; open; one or more lesions.				\$	513.87
19125	Excision of breast lesion identified by preoperative placement of radiological marker; open; single lesion.				\$	566.59
19126	Excision of breast lesion identified by preoperative placement of radiological marker, open; each additional lesion separately identified by a preoperative radiological marker.				\$	159.97
19281	Placement of breast localization device, percutaneous; mammographic guidance; first lesion.	7			\$	243.14
19282	Placement of breast localization device, percutaneous; mammographic guidance; each additional lesion.	7			\$	172.97
is a registe vised 05.28.2	red trademark of the American Medical Association. 2021				3	Page11

CPT Code	Screening and Diagnostic Procedures	End Note	Professional Component (-26)	Technical Component (-TC)	Total
19283	Placement of breast localization device, percutaneous; stereotactic guidance; first lesion.	7			\$ 268.23
19284	Placement of breast localization device, percutaneous; stereotactic guidance; each additional lesion.	7			\$ 204.03
19285	Placement of breast localization device, percutaneous; ultrasound guidance; first lesion.	7			\$ 423.18
19286	Placement of breast localization device, percutaneous; ultrasound guidance; each additional lesion.	7			\$ 356.55
19287	Placement of breast localization device, percutaneous; magnetic resonance guidance; first lesion.	7			\$ 726.40
19288	Placement of breast localization device, percutaneous; magnetic resonance guidance; each additional lesion.	7			\$ 572.91
57452	Colposcopy of the cervix.				\$ 123.59
57454	Colposcopy of the cervix, with biopsy and endocervical curettage.				\$ 167.03
57455	Colposcopy of the cervix, with biopsy.				\$ 158.68
57456	Colposcopy of the cervix, with endocervical curettage.				\$ 148.92
57460	Colposcopy with loop electrode biopsy(s) of the cervix.				\$ 317.94
57461	Colposcopy with loop electrode conization of the cervix.				\$ 354.18
57500	Cervical biopsy, single or multiple, or local excision of lesion, with or without fulguration (separate procedure).				\$ 152.38
57505	Endocervical curettage (not done as part of a dilation and curettage).				\$ 145.10
57520	Conization of cervix, with or without fulguration, with or without dilation and curettage, with or without repair; cold knife or laser.				\$ 346.38
57522	Loop electrode excision procedure.				\$ 298.01
58100	Endometrial sampling (biopsy) with or without endocervical sampling (biopsy), without cervical dilation, any method (separate procedure).				\$ 101.29
58110	Endometrial sampling (biopsy) performed in conjunction with colposcopy (List separately in addition to code for primary procedure).				\$ 50.33
T is a registe vised 05.28.2	red trademark of the American Medical Association. 2021				4 P a g e 1 1

CPT Code	Screening and Diagnostic Procedures	End Note	Professional Component (-26)		Con	chnical nponent (-TC)		Total
76098	Radiological examination, surgical specimen.		\$	15.40	\$	25.85	\$	41.25
76641	Ultrasound, complete examination of breast including axilla, unilateral.		\$	35.30	\$	69.32	\$	104.62
76642	Ultrasound, limited examination of breast including axilla, unilateral.		\$	33.22	\$	53.06	\$	86.28
76942	Ultrasonic guidance for needle placement, imaging supervision and interpretation.		\$	30.88	\$	26.18	\$	57.06
77046	Magnetic resonance imaging (MRI), breast, without contrast, unilateral.	5	\$	69.64	\$	163.86	\$	233.50
77047	Magnetic resonance imaging (MRI), breast, without contrast, bilateral.	5	\$	76.87	\$	163.20	\$	240.07
77048	Magnetic resonance imaging (MRI), breast, including CAD, with and without contrast, unilateral.	5	\$	101.49	\$	270.05	\$	371.53
77049	Magnetic resonance imaging (MRI), breast, including CAD, with and without contrast, bilateral.	5	\$	111.09	\$	268.72	\$	379.81
77053	Mammary ductogram or galactogram, single duct.		\$	17.47	\$	36.80	\$	54.27
77063	Screening digital breast tomosynthesis, bilateral.	3	\$	29.43	\$	24.22	\$	53.66
77065	Diagnostic mammography, unilateral, includes CAD.		\$	39.08	\$	86.91	\$	125.99
77066	Diagnostic mammography, bilateral, includes CAD.		\$	48.33	\$	111.13	\$	159.47
77067	Screening mammography, bilateral, includes CAD.	· ·	\$	37.01	Ś	91.89	Ś	128.89

CPT is a registered trademark of the American Medical Association. Revised 05.28.2021

5 | Page11

CPT Code	ASC Rates with Relevant CPT Codes	End Note	Facility Price (for Provider)	Facility Fee	
19000	Puncture aspiration of cyst of breast		\$ 42.89	\$ 106.27	
19081	Breast biopsy, with placement of localization device and imaging of biopsy specimen, percutaneous; stereotactic guidance; first lesion		\$ 163.86	\$ 564.38	
19083	Breast biopsy, with placement of localization device and imaging of biopsy specimen, percutaneous; ultrasound guidance; first lesion		\$ 154.90	\$ 564.72	
19084	Breast biopsy, with placement of localization device and imaging of biopsy specimen, percutaneous; ultrasound guidance; each additional lesion		\$ 77.15	\$ 442.50	
19085	Breast biopsy, with placement of localization device and imaging of biopsy specimen, percutaneous; magnetic resonance guidance; first lesion		\$ 179.78	\$866.35	
19100	Breast biopsy, percutaneous, needle core, not using imaging guidance		\$ 69.21	\$ 156.49	
19101	Breast biopsy, open, incisional		\$ 222.11	\$340.24	
19120	Excision of cyst, fibroadenoma or other benign or malignant tumor, aberrant breast tissue, duct lesion, nipple or areolar lesion; open; one or more lesions		\$ 413.65	\$ 513.87	
19125	Excision of breast lesion identified by preoperative placement of radiological marker; open; single lesion		\$ 458.08	\$ 556.59	
CPT Code	Pathology	End Note	Professional Component (-26)	Technical Component (-TC)	Total
Various	Pre-operative testing; CBC, urinalysis, pregnancy test, etc. These procedures should be medically necessary for the planned surgical procedure.				
87426	COVID-19 infectious agent detection by nuclei acid DNA or RNA; amplified probe technique.				\$ 35.33
	COVID-19 infectious agent antigen detection by immunoassay technique;				\$ 51.31
87635	qualitative or semiquantitative				
87635 88365	qualitative or semiquantitative In situ hybridization (e.g., FISH), per specimen; initial single probe stain procedure.		\$ 43.25	\$ 134.99	\$ 178.24

CPT is a registered trademark of the American Medical Association. Revised 05.28.2021 6 | P a g e 1 1

CPT Code	Pathology	End Note	Comp	ssional oonent 26)	Cor	echnical mponent (-TC)		Total
88366	In situ hybridization (e.g., FISH), per specimen; each multiplex probe stain procedure.		\$	61.45	\$	219.61	\$	281.06
88373	Morphometric analysis, in situ hybridization, computer-assisted, per specimen, each additional probe stain procedure.		\$	25.85	\$	44.80	\$	70.64
88374	Morphometric analysis, in situ hybridization, computer-assisted, per specimen, each multiplex stain procedure.		\$	43.37	\$	293.31	\$	336.68
88367	Morphometric analysis, in situ hybridization, computer-assisted, per specimen, initial single probe stain procedure.		\$	33.40	\$	77.95	\$	111.35
88368	Morphometric analysis, in situ hybridization, manual, per specimen, initial single probe stain procedure.		\$	40.96	\$	90.86	\$	131.82
88369	Morphometric analysis, in situ hybridization, manual, per specimen, each additional probe stain procedure.		\$	32.02	\$	81.60	\$	113.62
88377	Morphometric analysis, in situ hybridization, manual, per specimen, each multiplex stain procedure.		\$	63.72	\$	342.39	\$	406.10
87624	Human Papillomavirus, high-risk types.	9					\$	35.09
87625	Human Papillomavirus, types 16 and 18 only.	9				-	\$	40.55
88141	Cytopathology, cervical or vaginal, any reporting system, <u>requiring</u> interpretation by physician.						\$	21.32
88142	Cytopathology (liquid-based Pap test) cervical or vaginal, collected in preservative fluid, automated thin layer preparation; manual screening under physician supervision.						\$	20.26
88143	Cytopathology, cervical or vaginal, collected in preservative fluid, automated thin layer preparation; manual screening and rescreening under physician supervision.						\$	23.04
88164	Cytopathology (conventional Pap test), slides cervical or vaginal reported in Bethesda System, manual screening under physician supervision.						\$	15.12
88165	Cytopathology (conventional Pap test), slides cervical or vaginal reported in Bethesda System, manual screening and rescreening under physician supervision.						\$	42.22
T is a regist vised 05.28	ered trademark of the American Medical Association. 2021				•		7 P	age11

CPT Code	Pathology	End Note	Professional Technical Component Component (-26) (-TC)			t Total		
88172	Cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy of specimen(s), first evaluation episode.		\$	35.33	\$	18.88	\$	54.21
88173	Cytopathology, evaluation of fine needle aspirate; interpretation and report.	\square'	\$	69.94	\$	81.23	\$	151.17
88174	Cytopathology, cervical or vaginal, collected in preservative fluid, automated thin layer preparation; screening by automated system, under physician supervision.						\$	25.37
88175	Cytopathology, cervical or vaginal, collected in preservative fluid, automated thin layer preparation; screening by automated system and manual rescreening, under physician supervision.						\$	26 <mark>.</mark> 61
88177	Cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy of specimen(s), each separate additional evaluation episode.		\$	21.59	\$	6.97	\$	28.56
88305	Surgical pathology, gross and microscopic examination.	\square'	\$	37.09	\$	32.16	\$	69.24
88307	Surgical pathology, gross and microscopic examination; requiring microscopic evaluation of surgical margins.	[!	\$	81.90	\$	196.65	\$	278.54
88331	Pathology consultation during surgery, first tissue block, with frozen section(s), single specimen.		\$	61.37	\$	40.12	\$	101.49
88332	Pathology consultation during surgery, each additional tissue block, with frozen section(s).		\$	30.51	\$	22.86	\$	53.37
88341	Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure).		\$	28.14	\$	62.05	\$	90.19
88342	Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure.		\$	34.68	\$	67.33	\$	102.01
88360	Morphometric analysis, tumor immunohistochemistry, per specimen; manual.		\$	41.57	\$	78.61	\$	120.18

CPT is a registered trademark of the American Medical Association. Revised 05.28.2021

8 | Page11

CPT Code	Pathology	End Note	Cor	fessional nponent (-26)	Con	chnical nponent (-TC)		Total
88361	Morphometric analysis, tumor immunohistochemistry, per specimen; using computer- assisted technology.		\$	43.40	\$	76.29	\$	119.69
99070	Supplies and materials (except spectacles), provided by the physician over and above those usually included with the office visit or other services rendered (list drugs, trays, supplies, or materials provided).						Va	rious

HCPS Code	Transportation Services (AHCCCS Rates)			End Note	Amo	ount			
A0080	Non-emergency transportation, per mile, volunteer				\$ 0	44			
A0160	Non-emergency transportation, per mile, case worker				\$ 0	\$ 0.44			
A0100	Taxicab, base rate, per client				\$ 1	\$ 1.04			
S0215	Taxicab, rate/ per mile, urban				\$ 1.28				
A0100	Taxicab base rate, per client				\$ 1	.04			
S0215	Taxicab, rate/ per mile, rural				\$ 1	.53			
A0120	Ambulatory Van, urban base rate per client				\$6	.64			
S0215	Ambulatory Van, urban rate/ per mile			\$ 1	.28				
A0120	Ambulatory Van, rural base rate per client				\$ 7.27				
S0215	Ambulatory Van, rural rate/ per mile				\$ 1	\$ 1.53			
A0130	Wheelchair Van, urban base rate per client				\$ 11	\$ 11.15			
S0209	Wheelchair Van, urban rate/ per mile				\$ 1	\$ 1.54			
A0130	Wheelchair Van, rural base rate per client				\$ 12.21				
S0209	Wheelchair Van, rural rate/ per mile				\$ 1	.66			
CPT Code	Approved Pre-Operative Codes (ADHS Use Only)	End Note	Professi Compor (-26)	nent	Technical Component (-TC)	1	Fotal		
36415	Lab Draw					\$	3.0		
80048	Basic Metabolic Panel					\$	9.4		
85025	Blood Count					Ś	8.6		

Revised 05.28.2021

85610	Pro Thrombin			\$ 4.37
85730	Thromboplastin			\$ 6.67
81003	Urinalysis			\$ 2.49
71046	Radiological examination, CHEST - 2 Views	\$ 10.63	\$ 22.20	\$ 32.83
93005	EKG			\$ 6.27
81025	Pregnancy Test			\$ 8.61
Various	Pre-operative testing; CBC, urinalysis, pregnancy test, etc. These procedures should be medically necessary for the planned surgical procedure.			

CPT Code	Anesthesia	End Note	Professional Component (-26)	Technical Component (-TC)	Total
00400	Anesthesia for procedures on the integumentary system, anterior trunk, not otherwise specified				\$ 32.12
99156	Moderate anesthesia, 10-22 minutes for individuals 5 years or older				\$ 75.96
99157	Moderate anesthesia for each additional 15 minutes	10			\$ 62.50
CPT Code	Procedures Specifically Not Allowed	End Note			
Any	Treatment of breast carcinoma in situ, breast cancer, cervical intraepithelial neoplasia and cervical cancer.				
77061	Breast tomosynthesis, unilateral.	11	х	х	x
77062	Breast tomosynthesis, bilateral.	11	х	x	x
87623	Human papillomavirus, low-risk types.		х	x	x

CPT is a registered trademark of the American Medical Association. Revised 05.28.2021 10 | Page11

End Note	Description
1	All consultations should be billed through the standard "new patient" office visit CPT codes 99201–99205. Consultations billed as 99204 or 99205 must meet the criteria for these codes. These codes (99204–99205) are typically <u>not</u> appropriate for NBCCEDP screening visits. However, they may be used when provider spends extra time to do a detailed risk assessment.
2	The type and duration of office visits should be appropriate to the level of care needed to accomplish screening and diagnostic follow-up within the NBCCEDP. While some programs may need to use 993XX- series codes, Preventive Medicine Evaluation visits are not covered by Medicare and not appropriate for the NBCCEDP. The 9938X codes shall be reimbursed at or below the 99203 rate, and 9939X codes shall be reimbursed at or below the 99213 rate.
3	List separately in addition to code for primary procedure 77067.
4	List separately in addition to 77065 or 77066.
5	Breast MRI can be reimbursed by the NBCCEDP in conjunction with a mammogram when a client has a BRCA gene mutation, a first- degree relative who is a BRCA carrier, or a lifetime risk of 20% or greater as defined by risk assessment models such as BRCAPRO that depend largely on family history. Breast MRI also can be used to assess areas of concern on a mammogram, or to evaluate a client with a history of breast cancer after completing treatment. Breast MRI should never be done alone as a breast cancer screening tool. Breast MRI cannot be reimbursed for by the NBCCEDP to assess the extent of disease in a woman who has just been newly diagnosed with breast cancer in order to determine treatment.
6	Codes 19081–19086 are to be used for breast biopsies that include image guidance, placement of a localization device, and imaging of specimen. They should not be used in conjunction with 19281–19288.
7	Codes 19281–19288 are for image guidance placement of a localization device without image-guided biopsy. These codes should not be used in conjunction with 19081–19086.
8	For CPT 10011 use the reimbursement rate for CPT code 10009. For CPT 10012 use the reimbursement rate for CPT code 10010.
9	HPV DNA testing is not a reimbursable procedure if used as an adjunctive screening test to the Pap for women under 30 years of age.
10	Example: If procedure is 50 minutes, code 99156 + (99157 x 2). No separate charge allowed if procedure <10 minutes.
11	These procedures have not been approved for coverage by Medicare.

Note: all procedures over \$2,500.00 must have prior authorization.

CPT is a registered trademark of the American Medical Association. Revised 05.28.2021 **11 |** P a g e 1 1

Appendix F

Participant Demographic Variables

Table 1

Frequency Table for Demographic Variables

Variable	п	%
Marital Status		
Single	5	50.00
Married	3	30.00
Living with Partner	2	20.00
Race		
American Indian or Alaskan Native	2	20.00
White or Caucasian	5	50.00
Other	3	30.00
County		
Coconino	9	90.00
Yavapai	1	10.00
Education		
College	5	50.00
High School	2	20.00
Vocational College	1	10.00
Middle School	1	10.00
Graduate School	1	10.00
Insurance		
Private Insurance	3	30.00
Uninsured	7	70.00
Primary Language		
English	6	60.00
Spanish	4	40.00
Hispanic or Latino		
No	6	60.00
Yes	4	40.00

Table 2

Summary Statistics Table for Age, Annual Income, and Household Size

Variable	M	SD	n	Min	Max
Age	47.50	12.76	10	24.00	63.00
Annual Income	12,514.20	14,442.18	10	0.00	50,000.00
Household	2.58	1.26	10	1.00	5.00

Appendix G

General Health Demographic Variables

Table 3

Frequency Table for General Health Demographic Variables

Variable	n	%
Do you have a health care provider?		
Yes	7	70.00
No	3	30.00
When was the last time you visited your provider?		
<6 months	7	70.00
>1 year	2	20.00
6 months - 1 year	1	10.00
General Health		
Good	4	40.00
Fair	2	20.00
Excellent	2	20.00
Very Good	2	20.00

Table 4

Frequency Table Likert Scale General Health Demographics Variables

Variable	
How often do you prepare a list of questions for your doctor?	
Always	0.00
Often	0.00
Rarely	0.00
Sometimes	0.00
Never	0.00
How often do you ask questions about the things you want to kno and the things you don't understand?)W
Always	0.00

Table 4

Frequency Table Likert Scale General Health Demographics Variables

Variable	
Sometimes	0.00
Often	0.00
Rarely	0.00
How often do you discuss any personal problems that may be related to your illness?	
Always	0.00
Sometimes	0.00
Often	0.00
Rarely	0.00
How confident are you in filling out medical forms by yourself?	
Always	0.00
Often	0.00
Sometimes	0.00
Rarely	0.00

Table 5

Summary Statistics General Health Demographic Variables

Variable	M	SD	
How many days in the past month was your physical health not good?	0.00	0.00	
How many days in the past month was your mental health not good?	1.70	3.13	

Appendix H

Pap Smear History

Table 6

Frequency Table for Pap Smear History

Variable	n	%
Have you had a hysterectomy?		
No	9	90.00
Yes	1	10.00
Last pap smear		
1-2 years	1	10.00
Not sure	3	30.00
Within past 1 year	6	60.00
Abnormal pap smear		
No	5	50.00
n/a	4	40.00
Yes	1	10.00
Have you or a member of your family had cervical cancer?		
FALSE	9	90.00
TRUE	1	10.00
Are you aware of the 3-part HPV vaccine series?		
Yes	3	30.00
Not sure	1	10.00
No	6	60.00
Have you received the HPV vaccine?		
Yes	1	10.00
No	8	80.00
Not sure	1	10.00
Have you completed the HPV vaccine series?		
Yes	1	10.00
No	9	90.00

Appendix I

Cervical Cancer Risk Factors

Table 7

Frequency Table for Cervical Cancer Risk Factors

Variable	n	%
She has many sexual partners		
TRUE	5	50.00
Not sure	3	30.00
FALSE	2	20.00
She smokes cigarettes		
FALSE	4	40.00
TRUE	4	40.00
Not sure	2	20.00
She started having sex at a young age		
Not sure	2	20.00
TRUE	4	40.00
FALSE	4	40.00
She has unprotected sex		
TRUE	3	30.00
Not sure	3	30.00
FALSE	4	40.00
She does not go for regular pap smear tests		
TRUE	8	80.00
Not sure	1	10.00
FALSE	1	10.00
She has a sexually transmitted disease or virus		
TRUE	7	70.00
Not sure	1	10.00
FALSE	2	20.00
She used birth control pills for a long time		
FALSE	4	40.00
TRUE	3	30.00
Not sure	3	30.00
She has many children		
FALSE	5	50.00
TRUE	1	10.00
Not sure	4	40.00

She has a weakened immune system		
TRUE	3	30.00
Not sure	3	30.00
FALSE	4	40.00
It runs in her family		
TRUE	7	70.00
Not sure	1	10.00
FALSE	2	20.00

Appendix J

Socioeconomic Barriers to Routine Cervical Cancer Screening

Table 8

Frequency Table for Socioeconomic Barriers to Routine Cervical Cancer Screening

Variable	n	%
Feelings of embarrassment	·	
Strongly Disagree	8	80.00
Disagree	1	10.00
Neither Agree nor Disagree	1	10.00
Fear of finding cancer		
Strongly Disagree	7	70.00
Disagree	1	10.00
Agree	2	20.00
Transportation		
Strongly Disagree	9	90.00
Agree	1	10.00
Cost		
Strongly Disagree	5	50.00
Strongly Agree	1	10.00
Disagree	4	40.00
Anxiety about procedure		
Strongly Disagree	8	80.00
Neither Agree nor Disagree	1	10.00
Disagree	1	10.00
Lack of knowledge		
Strongly Disagree	9	90.00
Disagree	1	10.00
Lack of time		
Strongly Disagree	9	90.00
Disagree	1	10.00
Anticipation of pain		
Strongly Disagree	7	70.00
Disagree	2	20.00
Neither Agree nor Disagree	1	10.00

Table 8

Frequency Table for Socioeconomic Barriers to Routine Cervical Cancer Screening

Variable	п	%
Strongly Disagree	6	60.00
Neither Agree nor Disagree	2	20.00
Agree	1	10.00
Disagree	1	10.00
Other health problems		
Strongly Disagree	8	80.00
Disagree	2	20.00
Language barriers		
Strongly Disagree	7	70.00
Neither Agree nor Disagree	1	10.00
Agree	1	10.00
Disagree	1	10.00
Male physician		
Strongly Disagree	6	60.00
Strongly Agree	1	10.00
Neither Agree nor Disagree	2	20.00
Disagree	1	10.00